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ABSTRACT 
 
DEVELOPMENT OF A HIGH THROUGHPUT ASSAY TO OPTIMIZE 
HEMATOPOIETIC DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS 
Joel Thomas Outten 
Advisor: Scott L. Diamond 
 Human embryonic stem cells (hESCs) offer the potential to develop in vitro 
protocols for the generation of any human somatic cell.  In order for protocols to allow 
for both comprehension of underlying developmental mechanics and future clinical 
application, they will need to rely upon efficient differentiation of cells without the 
reliance upon animal-derived components.  This thesis presents the development of a 96-
well plate culture system that allows 4-color, flow cytometry based high throughput 
screening of defined, serum-free hESC differentiation conditions.  In the first portion, 
broad applicability is proven by demonstrating highly efficient differentiation toward the 
three primary germ layers.  Using four separate biomarkers, we were able to distinguish 
between ectoderm, endoderm, mesoderm and pluripotent hESCs.    We demonstrated the 
ability to perform both cytokine screens and siRNA-mediated knockdown in this assay.  
In the second portion, we establish conditions to apply this assay to study hematopoietic 
differentiation.  We performed numerous cytokine and inhibitor screens to develop a 
stepwise protocol that generates high yields of primitive megakaryocyte-erythromyeloid 
progenitors and megakaryocytes after 8 and 11 days of embryoid body differentiation, 
respectively.  This work provides a novel tool to streamline the development of hESC 
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differentiation protocols and advances the hematopoietic field towards future hESC-
derived therapies. 
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1. Introduction 
1.1 Human embryonic stem cells 
 The isolation of human embryonic stem cells (hESCs) in 1998 [1] has 
revolutionized the field of regenerative medicine.  hESCs, isolated from human 
blastocysts, exhibit pluripotency and can thus be theoretically induced to generate any 
somatic human cell.  These cells offer new approaches to study human development and 
organogenesis, screen candidate drug molecules for toxicities, treat previously incurable 
pathologies, generate lines of desired cell types, and study disease mechanisms.  Studies 
are increasingly being undertaken in all of these areas.  While these cells have vast 
scientific and medical potential, progress relies on scientists to identify repeatable 
techniques to control differentiation outcome.  Initial studies identified basic conditions 
to differentiate cells to the three primary germ layers [2, 3].  Somatic adult cells, in 
contrast, require lengthy differentiation pathways that must be tightly controlled and are 
infrequently understood.  Increasingly more studies focus on defining protocols by which 
to differentiate hESCs to target cell lineages. 
 
1.2 Mammalian development 
 hESCs are extracted from the inner cell mass of the approximately 6 day old 
blastocyst [3].  In mammalian development, the inner cell mass develops into the epiblast 
within a few days.  The onset of gastrulation is marked by the formation of the primitive 
streak on the surface of the epiblast around day 14.  Epiblast cells begin to migrate 
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through the primitive streak and differentiate into either mesoderm or definitive 
endoderm.  Epiblast cells that do not migrate through the streak will form the ectoderm.  
These three germ layers eventually differentiate into all the cells and tissues of the body 
[4]. 
 Gastrulation, as well as the entire process of development, is a highly coordinated, 
delicate interplay of growth factors and cytokines secreted and received at just the right 
moments.  The primitive streak itself is initiated by coordinated expression of the 
transforming growth factor-beta (TGF-b) family members Nodal and bone morphogenic 
protein 4 (BMP4) and members of the Wnt family.  The local concentration of these 
growth factors induces streak cells to migrate and begin differentiating toward the 
mesoderm and endoderm lineages.  The extraembryonic endoderm secretes BMP4 during 
gastrulation.  A BMP4 diffusion gradient is thus formed in which posterior primitive 
streak cells receive the highest exposure and anterior cells receive the lowest.  BMP4 
promotes mesoderm, inducing posterior streak cells to differentiate down this lineage.  
Conversely, high concentrations of Nodal, secreted by the node by late-streak stage, 
promote anterior streak cells to become definitive endoderm.  Members of the fibroblast 
growth factor (FGF) family, including FGF4 and FGF8, are also required for primitive 
streak formation and gastrulation.  The signaling pathways utilized during development 
are thoroughly reviewed in Gadue et al. [5] and Murry and Keller [6]. 
 In vitro experiments aim to recapitulate hESC development by mimicking the in 
vivo environment.  Developmental signals and cues in vivo can be utilized to structure 
differentiation protocols of hESCs.    Therefore, studies aim to follow developmental 
principles and pathways when differentiating to various lineages.  Conversely, hESC 
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studies can help elucidate pathways and developmental mechanisms to give a greater 
understanding of in vivo embryogenesis. 
 
1.3 Differentiation systems 
 Although scientists frequently know what target cell they aim to generate, the 
most appropriate path of differentiation is generally more elusive.  Three primary 
methods have been utilized to support differentiation systems: 1) embryoid body (EB) 
suspension culture, 2) adherent culture, and 3) co-culture with another cell line.  
Although the technique of choice depends upon the goal, the vast majority of studies 
have relied upon EB culture, and many protocols incorporate multiple methods. 
 
1.3.1 Embryoid body culture 
 When undifferentiated hESCs are seeded in suspension (generally as clumps of 
cells), cells aggregate and form spherical three-dimensional clusters called embryoid 
bodies.  Depending on external signaling cues, cells within EBs differentiate to one of the 
three primary germ layers as the EBs increase in size during differentiation.  EBs are 
generally cultured in one of four systems: 1) hanging drops 2) liquid suspension culture 
3) methylcellulose medium, and 4) large-scaleable bioreactors [7].  Each method carries 
advantages and disadvantages.  As a general principle, studies have shown that results are 
more reliable, dependable, and controllable when homogenous EBs of known sizes are 
utilized .   
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Hanging Drops 
 Although becoming less common, hanging drops have traditionally been widely 
used as a reliable method of generating consistent EBs of known size[8].  Individual 
drops of medium containing cells at a known density are attached to the underside of a 
plastic petri dish lid.  Cells aggregate in the rounded bottom of each drop and form an EB 
of defined cell number.  This method is becoming less common due to the time required 
to seed and harvest EBs. 
 
Liquid suspension culture 
 Many studies have relied on seeding single cells or clumps of ESCs into 6 to 24-
well culture plates.  EBs are formed either from spontaneous aggregation or from non-
dissociated clusters of cells [2, 9].  Due to the uncontrolled environment, EBs tend to be 
heterogenous in these systems[7].  EBs also have the potential to aggregate together 
during differentiation [10].  Rotary culture of EBs during differentiation has been 
demonstrated to induce homogenous EBs and increase yield and differentiation 
efficiency, albeit through an unknown mechanism [11].   More recently, groups have 
utilized micro-scale conical-patterned well inserts to generate hundreds of thousands of 
EBs from centrifugation of cells prior to seeding EBs in liquid suspension differentiation 
culture [12].  Similar technologies are now commercially available. 
 
Methylcellulose culture 
 Semisolid methylcellulose culture has been utilized to avoid uncontrolled 
aggregation and ensure the formation of single cell-derived EBs [13].  This method has 
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been used mostly for hematopoietic differentiation, but has become less frequent due to 
the difficulty of harvesting cells from methylcellulose. 
 
Large scale bioreactors 
 Many commercial and therapeutic applications of ESC protocols will require 
extremely large amounts of cells, negating the reliance on standard cell culture systems.  
Bioreactor systems can be scaled to meet such demands.  As with liquid culture systems, 
multiple EBs can aggregate in such systems, reducing the homogeneity of EB 
populations.  In order to minimize this phenomenon, EB formation is completed ahead of 
time, for instance in hanging drops[14], and then transferred to bulk stirred suspension 
cultures. 
 
1.3.2 Adherent and stromal cell co-culture 
 While EB culture supports ESC differentiation toward numerous lineages, several 
alternative approaches have been utilized to re-create a more developmentally-realistic 
stem cell niche. Both adherent and stromal cell co-culture aim to accomplish this goal.  
Adherent methods entail culturing ESCs as a two-dimensional monolayer on extracellular 
matrix proteins and allow for more control and generally exhibit less variability than EB 
protocols.  However, such protocols can not be scaled-up to bioreactor culture and have 
only been demonstrated to be applicable for a small number of differentiation pathways.  
Numerous animal stromal cells have been demonstrated to induce efficient 
differentiation.  Stromal cells derived from the murine aorta-gonad-mesonephros (AGM), 
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the fetal liver, and the bone marrow have all been utilized to efficiently differentiate 
ESCs towards the hematopoietic lineage [15]. 
 
1.4  Serum-free differentiation media 
 Early ESC protocols relied on the use of serum containing media due to the 
enhanced viability and efficient differentiation [1, 16-18].  However, serum contains a 
plethora of unknown factors, is significantly variable between lots, and is not clinically 
applicable.  To overcome these limitations, more recent feeder-free studies have focused 
on identifying serum-free media formulations [19-21].  Numerous combinations of 
cytokines, growth factors, and siRNA molecules are being evaluated in order to 
understand signaling pathways utilized during differentiation and to optimize 
differentiation protocols to target cell types.  By precisely activating or inhibiting the 
TGFb family, FGF, Wnt, and other  pathways at specific times, the developing embryo 
directs differentiation to all somatic cells of the body [5].  In vitro hESC differentiation 
systems attempt to recapitulate these developmental pathways by utilizing controlled 
concentrations of cytokines and inhibitors.  As differentiation proceeds down specific 
lineages, the possible number of cytokine combinations dramatically increases.   
 
1.5 Small scale platforms 
 In an effort to reduce the requisite time and materials needed to assess a large 
array of conditions and cytokine combinations, several groups have developed small-
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scale culture platforms.  Ng et al. have developed a 96-well spin embryoid body (EB) 
technique in which hESCs are spun down to form a single EB of a defined size within 
each well [22, 23].  This technique has been utilized to optimize differentiation to various 
stages in the hematopoietic lineage[24, 25].  Koike et al. have developed a 96-well 
murine ESC (mESC) differentiation system and explored effects of EB seeding density 
upon differentiation to cardiomyocytes [26, 27].  Both of these systems allow for a high 
degree of control over the medium environment, enabling precise identification of 
extrinsic factors that may influence EB differentiation.  However, due to the small 
seeding density utilized by both methods to generate single EBs and the tendency for cell 
counts to drop over the first five days of differentiation [24], it is unclear if enough cells 
would be available for readouts such as 96-well flow cytometry analyses without pooling 
wells.  Furthermore, these systems cannot be scaled up to larger platforms, limiting the 
number of EBs that can be produced.  Several studies have utilized an adherent 384-well 
plate format to screen for small molecule inhibitors or enhancers of ESC differentiation 
[28, 29].  Although these confocal microscopy-based assays have been utilized to screen 
several thousand small molecules, they are not conducive to multi-color flow-cytometry 
or live cell sorting and would only be applicable to adherent culture protocols. 
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2. Materials and Methods  
2.1 hESC maintenance 
 HES2 (passage 26-34) and H9 cells (passage 35-65) were maintained on 
irradiated mouse embryonic fibroblasts (MEFs) in hESC maintenance medium consisting 
of DMEM/F12 50:50 (Mediatech) supplemented with 20% Knockout Serum (Invitrogen, 
Carlsbad, CA), 1x non-essential amino acids (Invitrogen), 0.55 mM b-mercaptoethanol, 
1% penicillin/streptomycin, 2 mM glutamine (Invitrogen), and 20 ng/mL bFGF (R&D 
Systems, Minneapolis, MN).  Cells were passaged at 1:3-1:6 ratios using 0.25% 
trypsin/EDTA (Mediatech, Manassas, VA) or TrypLE Express (Invitrogen).  For siRNA 
experiments, a previously established HES2 line was utilized that expresses a red 
fluorescent protein (RFP) from the hROSA26 locus (HES2-R26) [30].   
   
2.2 hESC differentiation 
2.2.1 Germ layer differentiation 
 A 6-day differentiation procedure was utilized (Fig. 3.1A).  Prior to 
differentiation, hESCs were trypsinized and replated on matrigel (Becton Dickinson, 
Franklin Lakes, NJ) in hESC maintenance medium.  Serum-free differentiation (SFD) 
medium consisted of 75% IMDM (Invitrogen), 25% F12 (Mediatech), 0.5x N-2 
supplement (Invitrogen) 0.5x B27 without retinoic acid (Invitrogen), and 0.05% BSA 
(Sigma, St. Louis, MO).  Upon 75% confluency, cells were trypsinized, harvested with a 
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cell scraper, spun down, and resuspended in SFD medium supplemented with 
penicillin/streptomycin, 2 mM glutamine, 0.5 mM ascorbic acid (Sigma), 1.5x10-4 M 
monothioglycerol (Sigma), and the specified concentrations of cytokines as indicated 
(summarized in Table 2.1).  Day 0 media was supplemented with: 10 ng/mL BMP4 
(R&D Systems) for endoderm/mesoderm or 10 mM SB431542 (Tocris, Ellisville, MO), 
500 ng/mL BMPR1A (R&D Systems), and 5 ng/mL bFGF (R&D Systems, Minneapolis, 
MN) for ectoderm.  2x106 cells were seeded into 10-cm petri dishes and cultured at 5% 
CO2/5% O2/90% N2.  After 24 hours, EBs were harvested, manually disrupted, and 
seeded into 100 mL Day 1 medium into low-cluster 96-well plates (Corning, Corning, 
NY) at 2x105 cells/mL (2x104 cells/well).  Endoderm Day 1 medium was supplemented 
with 100 ng/mL activin A (R&D Systems), 2.5 ng/mL bFGF, 0.5 ng/mL BMP4.  
Mesoderm Day 1 medium was supplemented with 0.5 ng/mL activin A, 2.5 ng/mL bFGF, 
and 20 ng/mL BMP4.  Ectoderm Day 1 medium was supplemented with 5 ng/mL bFGF, 
10 mM SB431542, and 500 ng/mL BMPR1A.  For growth factor screening experiments, 
Day 1 media contained 2.5 ng/mL bFGF, and activin A and BMP4 were utilized at 
concentrations of 0 to 100 ng/mL, as indicated.  At Day 4, 200 mL of Day 4 media were 
added to each well.  Day 4 mesoderm and endoderm media were identical to Day 1 
media, but with 5 ng/mL bFGF.  Day 4 ectoderm medium was identical to Day 1 medium 
with 20 ng/mL bFGF.  For growth factor screening experiments, media were 
supplemented with 5 ng/mL bFGF, the indicated concentrations of activin A and BMP4, 
and ± 10 ng/mL VEGF165 (R&D Systems).  During incubation, 96-well plates were 
covered with gas-permeable membranes (Breathe Easy, Diversified Biotech, Boston, 
MA) and stainless steel plate lids (Kalypsys, Inc., San Diego, CA). 
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Table 2.1.  Differentiation media for germ layer induction 
  
 
2.2.2 Hematopoietic differentiation 
 Cells were harvested from matrigel upon reaching 70-80% confluency by 
enzymatic cleavage with TrypLE Express for 4 min at RT.  Cells were removed with a 
cell scraper, spun down at 1200 rpm for 3 min, and resuspended in differentiation buffer.   
Differentiation medium consisted of StemPro-34 serum-free medium (SP34 SFM; 
Invitrogen) supplemented with penicillin/streptomycin, 2 mM glutamine, 0.5 mM 
ascorbic acid, 1.5x10-4 M monothioglycerol, and growth factors and inhibitors as 
specified in Results.  Resuspended cell clusters were partially disrupted by pipetting up 
and down 3-4 times with a serological pipet.  Depending upon experiment, the following 
cytokines and inhibitors were added at specified concentrations at designated stages of 
 Day 0 Day 1 Day 4 
Endoderm •2 mM Glutamine 
(Invitrogen) 
•0.5 mM ascorbic acid 
(Sigma) 
•1.5x10-4 M 
monothioglycerol (Sigma) 
•10 ng/mL BMP4 (R&D 
Systems) 
 
•2 mM Glutamine 
•0.5 mM ascorbic acid 
•1.5x10-4 M 
monothioglycerol 
•0.5 ng/mL BMP4 
•100 ng/mL Activin A 
(R&D Systems) 
•2.5 ng/mL bFGF (R&D 
Systems) 
•2 mM Glutamine 
•0.5 mM ascorbic acid 
•1.5x10-4 M 
monothioglycerol 
•0.5 ng/mL BMP4 
•100 ng/mL Activin A 
•5 ng/mL bFGF 
Mesoderm Identical to Day 0 endoderm •2 mM Glutamine 
•0.5 mM ascorbic acid 
•1.5x10-4 M 
monothioglycerol 
•20 ng/mL BMP4 
•0.5 ng/mL Activin A 
•2.5 ng/mL bFGF 
•2 mM Glutamine 
•0.5 mM ascorbic acid 
•1.5x10-4 M 
monothioglycerol 
•20 ng/mL BMP4 
•0.5 ng/mL Activin A 
•5 ng/mL bFGF 
Ectoderm •2 mM Glutamine 
•0.5 mM ascorbic acid 
•1.5x10-4 M 
monothioglycerol  
•500 ng/mL BMPR1A 
(R&D Systems) 
•10 mM SB431542 (Tocris) 
•5 ng/mL bFGF 
Identical to Day 0 ectoderm •2 mM Glutamine 
•0.5 mM ascorbic acid 
•1.5x10-4 M 
monothioglycerol 
•500 ng/mL BMPR1A 
•10 mM SB431542 
•20 ng/mL bFGF 
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differentiation as described in Results: 0-40 ng/mL BMP4, 0-100 ng/mL VEGF, 5-10 
ng/mL bFGF, TPO, Flt3-L, IL-3, IL-6 (all R&D Systems), Chir-99021 (Stemgent), and 
Y-27632 (Tocris).  Cells were seeded at 20,000 cells/well into 96-well ultra-low 
attachment plates.  To isolate day 7 single cells for further differentiation and 
methylcellulose cultures, wells were pooled and EBs allowed to settle for several 
minutes.  Supernatant was then withdrawn to extract single cells.  For further 
hematopoietic differentiation, single cells were transferred to 6-well ultra-low adherence 
plates and cultured in SP34 based medium supplemented with penicillin/streptomycin, 2 
mM glutamine, 0.5 mM ascorbic acid, 1.5x10-4 M monothioglycerol, 50 ng/mL SCF, 100 
ng/mL TPO, 2 U/mL EPO, 25 ng/mL Flt3-L, 10 ng/mL IL-6, and 10 ng/mL IL-3. 
 
2.3 96-well flow cytometry 
2.3.1 Germ layer differentiation 
 EBs were dissociated, stained, and analyzed via 96-well flow cytometry as 
described [31].  EBs were transferred to 96-well V-bottom plates, spun down, and 
dissociated with 0.25% trypsin/EDTA.  Antibodies utilized were: rat anti-SSEA-3-Alexa 
488 (Biolegend, San Diego, CA, 330306), mouse anti-CXCR4-PE (Invitrogen, 
MHCCXCR404), mouse anti-NCAM-PE/Cy7 (Biolegend, 318318), mouse anti-KDR-
Alexa 647 (Biolegend, 338909), mouse anti-PDGFRa-biotin (Biolegend, 323503), and 
streptavidin-PE/Cy7 (Invitrogen, SA1012).  Cells were acquired directly from 96-well 
plates using a C6 Flow Cytometer equipped with a 96-well plate C-Sampler (Accuri, Ann 
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Arbor, MI) and analyzed using CFlow Plus software (Accuri) or FlowJo (Treestar, 
Ashland, OR).  Markers utilized for flow cytometry are given in Table 2.2. 
Table 2.2.  Extracellular markers used for flow cytometry analyses 
 
Extracellular marker Alternative names Expression 
KDR (kinase insert 
domain receptor) 
VEGFR2, FLK1, CD309 Many mesoderm 
subpopulations and on 
pluripotent stem cells. 
SSEA-3 (stage-specific 
antigen 3) 
 Pluripotent stem cells and 
early ectoderm.  
Expression decreases with 
advanced differentiation. 
CXCR4 (chemokine C-X-
C motif receptor 4) 
 Endoderm and certain 
mesoderm subpopulations. 
NCAM (neural cell 
adhesion molecule) 
NCAM1, CD56 Early ectoderm and many 
endoderm and mesoderm 
subpopulations. 
PDGFRa (platelet-derived 
growth factor receptor a) 
CD140a Mesoderm subpopulations.  
Indicative of paraxial 
commitment in murine 
stem cell differentiation. 
CD31 PECAM-1 
(platelet/endothelial cell 
adhesion molecule) 
Hematopoietic and 
endothelial cells. 
CD34  Many hematopoietic 
populations. 
CD43 sialophorin Many hematopoietic 
populations. 
CD41 CD41B, GP aIIb, integrin 
aIIb 
Megakaryocyte 
progenitors and committed 
megakaryocytes. 
CD42a GP IX (glycoprotein IX) Committed 
megakaryocytes. 
CD235a GYPA (glycophorin A) Erythrocyte progenitors 
and committed 
erythrocytes. 
CD45 PRPRC (protein tyrosine 
phosphatase, receptor type 
C) 
Mature hematopoietic and 
myeloid cells. 
CD18 ITGB2 (integrin beta 2) Myeloid cells. 
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2.3.2 Hematopoietic differentiation 
 EBs were dissociated with either 0.25% trypsin/EDTA or with Collagenase B 
(Roche) followed by Accutase (Invitrogen).  Antibodies utilized were: rat anti-SSEA-3-
Alexa 488, mouse anti-KDR-Alexa 647 (Biolegend), mouse anti-CD31 PE/Cy7 
(Biolegend), mouse anti-CD34 Alexa 488 (Biolegend), mouse anti-CD43 FITC 
(Biolegend), mouse anti-CD43 PE (Biolegend), mouse anti-CD41 APC (Biolegend), 
mouse anti-CD41 PE (Biolegend), mouse anti-CD42a PE (BD Pharmingen), mouse anti-
CD45 PE/Cy7 (Biolegend), and mouse anti-CD235a APC (BD Pharmingen).  Cells were 
analyzed with 96-well flow cytometry as discussed previously.   
 
2.4 Real-time quantitative PCR 
 EBs were collected from wells and dissociated with 0.25% trypsin/EDTA.  Cells 
were lysed with the facilitation of QiaShredder columns and RNA was harvested using an 
RNeasy Mini-kit and treated with RNase-free DNase (Qiagen, Valencia, CA).  Reverse 
transcription was performed with the iScript cDNA synthesis kit (Bio-rad, Hercules, CA) 
or the High Capacity cDNA Reverse Transcription kit (Applied Biosystems).  Real-time 
quantitative PCR (qPCR) was performed in triplicate on a Roche Lightcycler 480 using 
LightCycler 480 SYBR Green I master mix (Roche, Indianapolis, IN) and 500 nM primer 
concentrations (Table 2.3).  All gene expression levels were normalized to the 
housekeeping gene GAPDH [24]. 
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Table 2.3.  Primers utilized for real-time quantitative PCR analysis 
 
2.5 siRNA knockdown 
 HES2 cells stably expressing RFP (HES2-R26 cells) [30] were reverse transfected 
at the time of 96-well plate seeding at Day 1.  2x104 cells in 100 uL of day 1 endoderm 
Gene  Sequence Amplicon 
Length 
OCT4 forward GCAAAACCCGGAGGAGTC 113 
 reverse CCACATCGGCCTGTGTATATC  
NANOG forward ATGCCTCACACGGAGACTGT 66 
 reverse AGGGCTGTCCTGAATAAGCA  
GSC forward ACCTCCGCGAGGAGAAAG 107 
 reverse GTTCCACTTCTCCGCGTTC  
SOX17 forward CGCCGAGTTGAGCAAGAT 113 
 reverse GGTGGTCCTGCATGTGCT  
FOXA2 forward CCGTTCTCCATCAACAACCT 89 
 reverse GCCTTGAGGTCCATTTTGTG  
CXCR4 forward CTGTGAGCAGAGGGTCCAG 60 
 reverse ATGAATGTCCACCTCGCTTT  
CER1 forward GGGAGACCTGCAGGACAGT 142 
 reverse CAGGAGGTATGGGAGTGCTG  
Brachyury forward TTCAAGGAGCTCACCAATGA 108 
 reverse GAAGGAGTACATGGCGTTGG  
KDR forward CAGGATGCAGAGCAAGGTG 93 
 reverse TCAAGAGAAACACTAGGCAAACC  
PDGFRa forward CCACCTGAGTGAGATTGTGG 83 
 reverse TCTTCAGGAAGTCCAGGTGAA  
PDGFRb forward AGGCTGGCCACTACACCAT 91 
 reverse AGCACTCGGACAGGGACAT  
MEOX1 forward AAATCATCCAGGCGGAGAA 95 
 reverse AAGGCCGTCCTCTCCTTG  
PAX6 forward CAAATAACCTGCCTATGCAACC 94 
 reverse TAACTCCGCCCATTCACC  
SOX1 forward CAGGCCATGGATGAAGGA 65 
 reverse CTTAATTGCTGGGGAATTG  
Nestin forward GAGGTGGCCACGTACAGG 86 
 reverse AAGCTGAGGGAAGTCTTGGA  
NCAM forward CTGCATTGCTGAGAACAAGG 80 
 reverse CATATGTGATTTTGGGTTTTGC  
CD34 forward GCGCTTTGCTTGCTGAGT 67 
 reverse GGGTAGCAGTACCGTTGTTGT  
RFP forward CTGAAGGGCGAGATCCAC 82 
 reverse TGGCCATGTAGATGGTCTTG  
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media were seeded onto a 20 mL transfection volume of Optimem I Reduced Serum 
Media (Invitrogen) containing 0.2 mL RNAiMax per well (Invitrogen) and 10 nM of 
either a non-specific scramble siRNA (Applied Biosystems, Foster City, CA) or a siRNA 
designed to target the RFP mRNA (IDT, Coralville, IA).  Day 1 total well volume was 
thus 120 uL.  Control samples were seeded into Optimem Media.  RNAiMax was utilized 
due to its high efficiency of delivering siRNA into hESCs [32].  Differentiation was 
performed as previously described, in which 200 uL medium at Day 4 was subsequently 
added to each well. 
 
2.6 Colony forming assays 
 EBs were dissociated as described in flow cytometry.  20,000 cells were diluted 
600 uL IMDM supplemented with the following cytokines: 10 U/mL EPO (Amgen), 5 
ng/mL GM-SCF (R&D Systems), 10 ng/mL IL-3, and 5 ng/mL GM-CSF (R&D 
Systems).  The cell/cytokine cocktail was transferred to 4 mL thawed methylcellulose 
medium (MethoCult; StemCell Technologies) and vortexed.  1 mL was transferred to 
each of 3 35-mm Petri dishes and incubated at 37ºC and 5% CO2 for 12 days. 
 
2.7 Hematologic stains 
 Selected colonies from methylcellulose culture or cells harvested from suspension 
differentiation cultures were washed in PBS and spun onto glass slides with a cytospin 
apparatus (Eppendorf) at 800 rpm for 3 min.  Slides were stained for 3 min in May-
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Grunwald fixation buffer, washed twice in dH2O, and stained with Wright-Giemsa stain 
for 18 min.   
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3. Development of a 96-well hESC Differentiation 
Assay 
 
3.1 Abstract 
 Serum-free differentiation protocols of human embryonic stem cells (hESCs) 
offer the ability to maximize reproducibility and to develop clinically applicable 
therapies.  We developed a high throughput, 96-well plate, 4-color flow cytometry-based 
assay to optimize differentiation media cocktails and to screen a variety of conditions.  
We were able to differentiate hESCs to all three primary germ layers, screen for the effect 
of a range of activin A, BMP4, and VEGF concentrations upon endoderm and mesoderm 
differentiation, and perform RNA-interference (RNAi)-mediated knockdown of a 
reporter gene during differentiation.  Cells were seeded in suspension culture and 
embryoid bodies were induced to differentiate to the 3 primary germ layers for 6 days.  
Endoderm (CXCR4+), mesoderm (KDR+), and ectoderm (SSEA-3+/NCAM+) 
differentiation yields were 75 ± 3%, 96 ± 2%, and 62 ± 3%, respectively.  Germ layer 
identities were confirmed by quantitative PCR.  Activin A, BMP4, and bFGF drove 
differentiation, with increasing concentrations of activin A inducing higher endoderm 
yields and increasing BMP4 inducing higher mesoderm yields.  VEGF drove lateral 
mesoderm differentiation.  RNAi-mediated knockdown of constitutively expressed red 
fluorescent protein did not affect endoderm differentiation.  This assay facilitates the 
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development of serum-free protocols for hESC differentiation to any target lineage and 
creates a platform for screening small molecules or RNAi during ESC differentiation.  
3.2 Introduction 
 Human embryonic stem cells (hESCs) offer the potential to regenerate any cell in 
the human body.  Initially, many studies utilized serum-containing media to develop 
differentiation protocols for target cell types [3, 16-18].  Serum, however, contains 
unknown and variable concentrations of growth factors and proteins.  More recently, 
serum-free differentiation (SFD) protocols have emerged in order to maximize 
reproducibility and to gain a more thorough understanding of biological pathways 
activated during differentiation to specified lineages [19-21, 33].  Numerous 
combinations of cytokines, growth factors, and siRNA molecules are being evaluated in 
order to understand signaling pathways utilized during differentiation and to optimize 
differentiation protocols to target cell types.  By precisely activating or inhibiting the 
TGFb family, FGF, Wnt, and other  pathways at specific times, the developing embryo 
directs differentiation to all somatic cells of the body [5].  In vitro hESC differentiation 
systems attempt to recapitulate these developmental pathways by utilizing controlled 
concentrations of cytokines and inhibitors.  As differentiation proceeds down specific 
lineages, the possible number of cytokine combinations dramatically increases.  A high 
throughput screening method that streamlines the analysis of various growth factor 
combinations and their effect upon differentiation would be extremely beneficial. 
 Only a few groups have developed small scale ESC differentiation systems in 
order to probe biological pathways and optimize differentiation media cocktails.  Ng et 
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al. [22, 23] have developed a 96-well spin embryoid body (EB) technique in which 
hESCs are spun down to form a single EB of a defined size within each well.  This 
technique has been utilized to optimize differentiation to various stages in the 
hematopoietic lineage [24, 25].  Koike et al. have developed a 96-well murine ESC 
(mESC) differentiation system and explored effects of EB seeding density upon 
differentiation to cardiomyocytes [26, 27].  Due to the small seeding density utilized by 
both methods to generate single EBs and the tendency for cell counts to drop over the 
first five days of differentiation [24], it is unclear if enough cells would be available for 
96-well flow cytometry analyses without pooling wells.  Several studies have utilized an 
adherent 384-well plate format to screen for small molecule inhibitors or enhancers of 
ESC differentiation  [28, 29].  Although these confocal microscopy-based assays have 
been utilized to screen several thousand small molecules, they are not conducive to multi-
color flow-cytometry or live cell sorting. 
 RNA interference (RNAi)-mediated gene knockdown has also become a common 
technique to explore gene involvement in active pathways.  siRNA knockdown of 
reporter genes does not affect pluripotency in hESCs grown on mouse embryonic 
fibroblasts (MEFs) [34].  Knockdown of OCT4 and NANOG have been shown to induce 
differentiation and loss of pluripotency in hESCs [35-37].  RNAi has been utilized to 
elucidate signaling pathways that mediate ESC differentiation to multiple lineages [38].  
Despite the potential that RNAi offers for understanding biology and modifying pathway 
activation, there is little data available regarding any potential off-target effects this 
technique may have upon targeted hESC differentiation.   
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 We have developed a small scale, flow cytometry-based, high throughput hESC 
EB differentiation assay.  In this study, we differentiate hESCs to the three primary germ 
layers and demonstrate biomarker profiles unique to each cell type.  We obtained high 
cell yields for each layer with remarkably low well-to-well variability.  We also 
demonstrate the ability to perform small interfering RNA (siRNA)-mediated gene 
knockdown at this scale without disrupting induced differentiation.  These results 
demonstrate the utility and efficacy of this system for efficiently optimizing SFD 
conditions and performing siRNA knockdown upon numerous targets. 
 
 
3.3 Results 
3.3.1 EB differentiation in 96-well format 
 We optimized a 96-well plate, 4-color flow cytometry assay for analyzing surface 
markers during hESC EB differentiation into target lineages.  A stepwise EB 
differentiation protocol was modified to differentiate the cells for 6 days (Fig. 3.1A) [39].  
A 4-color biomarker-based flow cytometry assay to detect cells representative of all three 
primary germ layers and undifferentiated hESCs in a single sample was developed (Fig. 
3.1B).  Combinations of the surface markers CXCR4, KDR, NCAM, and SSEA-3 were 
assessed to differentiate each cell type.  CXCR4 is a reliable marker for definitive 
endoderm [40], but is also expressed in migrating mesoderm [41].  KDR has frequently 
been utilized to characterize early mesoderm prior to diverging to a KDR+ lateral lineage 
or a PDGFRa+ paraxial lineage [42, 43] and is also expressed at low levels by hESCs 
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[39].  SSEA-3 is a marker of pluripotency expressed by hESCs.  Upon differentiation, 
SSEA-3 expression is lost [44, 45], although expression is maintained at the early 
neuroectoderm, neural stem cell stage [46].  NCAM (or CD56) is a neural marker whose 
expression is induced during this early ectoderm stage [46] and is a general marker for 
ectoderm differentiation [47].  However, NCAM expression is not unique to ectoderm but 
is expressed by some endoderm and mesoderm cells as well [48, 49].  Therefore, we 
utilized SSEA-3+NCAM- expression to characterize hESCs, CXCR4+KDR- expression 
for endoderm, SSEA-3+NCAM+ expression for ectoderm, and KDR+SSEA-3- expression 
for mesoderm. 
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Figure 3.1.  Experiment schematic and differentiation model.  (A) 6-day stepwise 
hESC EB differentiation schematic.  Differentiation protocols were established in 
which cells were fed at days 0, 1, and 4.  Cells were seeded into 96-well plates at 
day 1 and analyzed by 96-well flow cytometry at day 6.  (B) Differentiation and 
biomarker expression model.  A four-biomarker combination was designed in which 
hESCs and cells representing the three primary germ layers could be analyzed in a 
single sample. 
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 In order to examine inter-well variability and percent differentiation, one 96-well 
plate was partitioned into 3 induction media zones: endoderm, mesoderm, and ectoderm.  
We utilized high activin A with bFGF to induce endoderm [16], high BMP4 with bFGF 
to induce mesoderm [39], and simultaneous activin inhibition (SB431542) and BMP4 
inhibition (BMP receptor 1A; BMPR1A) with bFGF to induce ectoderm [50, 51] (Fig. 
3.1B).  The EBs appeared robust and morphologically similar to those grown in bacterial 
grade dishes and 6-well plates.  96-well flow cytometry was performed and the different 
populations of cells were defined from expression of the four biomarkers (Fig. 3.2A-B, 
Fig. 3.3).  HES2 endoderm (CXCR4+KDR-), mesoderm (KDR+SSEA-3-), and ectoderm 
(SSEA-3+NCAM+) differentiation yields were 74 ± 9%, 74 ± 17%, and 57 ± 8%, 
Figure 3.2.  Biomarker time-course analysis.  Germ layer differentiation was 
initiated at day 0.  SSEA-3, NCAM, CXCR4, and KDR surface marker expression 
was assessed with flow cytometry at days 0, 2, 4, and 6.   (A) Endoderm 
differentiation flow cytometry profiles.  Colored quadrants represent 
undifferentiated cells (brown) and differentiation to endoderm (blue), ectoderm 
(yellow), and mesoderm (red).  Similar mesoderm and ectoderm plots are given in 
Figure S1.  (B) Marker expression profiles for all differentiation conditions over 6 
days of differentiation 
A 
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respectively (Fig. 3.4E).  H9 cells demonstrated similar yields of 80 ± 11%, 78 ± 7%, and 
41 ± 9% for endoderm, mesoderm, and ectoderm, respectively (Fig. 3.4F).  Inter-well 
variability was remarkably low between identical induction conditions (Fig. 3.4A-D), 
with standard deviations consistently less than 4%.  Activin-/BMP-inhibited media 
Figure 3.3.  Mesoderm and ectoderm differentiation time course biomarker 
expression.  Cells were harvested at days 0, 2, 4, and 6 from (A) mesoderm (high 
BMP4) and (B) ectoderm (SB431542, BMPR1A) differentiation cultures and 
assessed for SSEA-3, NCAM, CXCR4, and KDR expression.  Colored quadrants 
represent undifferentiated cells (brown) and differentiation to endoderm (blue), 
ectoderm (yellow), and mesoderm (red).  Abbreviations: SSEA-3, stage-specific 
embryonic antigen-3; CXCR, CXC chemokine receptor; KDR, kinase insert domain 
receptor; PDGFRa, platelet-derived growth factor-a; BMP, bone morphogenetic 
protein. 
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retained expression characteristics of pluripotent hESCs (28 ± 17% SSEA-3+NCAM-), 
although NANOG and OCT4 transcript expression indicated this is likely due to retained 
expression of SSEA-3 in non-NCAM expressing ectoderm (Fig. 3.7A). 
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Figure 3.4.  Day 6 phenotypes after differentiation to the three germ layers.  (A-D) 
Inter-well variability for 96-well flow cytometry expression profiles.   hESCs were 
seeded into a 96-well plate and differentiated to endoderm, mesoderm, or ectoderm.  
Cells were stained for SSEA-3, CXCR4, NCAM, and KDR after 6 days to assess 
inter-well variability and the ability to distinguish the separate germ layers.  Plots 
show percentages of cells expressing the designated surface marker.  (E-F) 
Biomarker profiles for HES2 and H9 differentiation.  Each of the 4 cell types 
(hESCs, endoderm, mesoderm, ectoderm) was characterized by a unique biomarker 
expression profile.  The 96-well format demonstrated highly efficient differentiation 
to all three lineages.  Error bars represent well means of (E) 2 independent 
experiments (n = 2) ± SD and (F) 3 independent experiments (n = 3) ± SD.  Each 
germ layer was significantly different for its appropriate biomarker at the p < 0.01 
level (student’s t-test). 
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 Cells displayed some toxicity after being seeded at day 0 and then demonstrated 
proliferation after 2 days of differentiation (Fig. 3.5).  Both endoderm and mesoderm 
conditions yielded 4 to 6 day cell counts similar to the initial seeding density of 2x104 
cells/well, indicating a potential population plateau for these media.  Ectoderm cell yields 
(day 6 cell counts compared to day 0 seeding densities) were greater than 300% at day 6, 
possibly attributable to the addition of 20 ng/mL bFGF at day 4.  In order to evaluate the 
effect of seeding density upon differentiation efficiency, we evaluated day 6 marker 
expression levels for seeding densities of 8x103 to 6x104 cells/well (Fig. 3.6).  The assay 
proved to be highly robust for differences in cell densities.  Undifferentiated populations 
increased with increasing densities, as to be expected due to nutrient and cytokine 
depletion.  Mesoderm and ectoderm differentiation efficiency showed a gradual 
Figure 3.5.  Differentiation culture cell yield analysis.  H9 hESCs were seeded into 
96-well plates at day 0 at 20,000 cells/well and differentiated utilizing one of the 
three differentiation media: High Activin (endoderm), high BMP4 (mesoderm), and 
SB431542, BMPR1A (ectoderm).  Cell viability was assessed at days 2, 4, and 6.  
Error bars represent the mean ± SD of two independent experiments, each obtained 
from the mean of 6 wells on a single plate assay.  
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decreasing trend with increasing seeding density, whereas endoderm efficiency was 
essentially constant. 
 The differentiated populations of cells representative of each primary germ layer, 
as well as undifferentiated hESCs, display a unique biomarker profile (Fig. 3.4E-F).  
Each cell type was distinguished by increased expression of a combination of biomarkers.  
Figure 3.6.  hESC seeding density analysis.  H9 hESCs were seeded at the specified 
density into 96-well plates and differentiated to endoderm (high Activin), mesoderm 
(high BMP4), or ectoderm (SB431542, BMPR1A).  Expression of SSEA-3, 
CXCR4, NCAM, and KDR was analyzed with 96-well plate flow cytometry at day 
6.  Error bars represent the mean ± SD of 3 wells from a single plate assay. 
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These findings suggest that this 4-biomarker assay can be utilized to distinguish four 
unique cell types after 6 days of differentiation.  Furthermore, the three differentiated cell 
types have a biomarker profile characteristic of either endodermal, mesodermal, or early 
ectodermal cells. 
 
3.3.2 Gene expression verification of induced germ layers 
 In order to verify that the surface marker profiles obtained using flow cytometry 
corresponded to the anticipated lineages, real-time quantitative PCR (qPCR) was 
performed on RNA harvested from day 0 hESCs and from cells after 6 days of 
differentiation in the various differentiation conditions.  The pluripotency genes NANOG 
and OCT4 were expressed in undifferentiated cells and as expected were downregulated 
in the three conditions inducing cellular differentiation (Fig. 3.7A).  The anterior 
primitive streak gene FOXA2 was drastically upregulated in the high activin endoderm 
induction conditions, as were the anterior definitive endoderm genes SOX17 and CER1 
(Fig. 3.7B).  Figure 3.7C displays characteristic gene expression profiles representative of 
cells within the posterior primitive streak and differentiating toward mesoderm.  These 
genes were upregulated in conditions using high BMP4, and are representative of early 
stage as well as paraxial (PDGFRa) and lateral progenitor mesoderm (GATA2).  Dual 
BMP4 and activin A inhibition increased both PAX6 and SOX1 transcript expression 
(Fig. 3.7D).  The neuronal marker NESTIN was not upregulated in the ectoderm induction 
conditions, indicating that these cells have not yet begun to undergo neuralization [52].  
These gene expression data support the flow cytometry profiles showing that the three 
   30 
defined induction conditions differentiate the cells into lineages representative of 
endodermal, mesodermal, and early ectodermal germ layers. 
 
 
Figure 3.7.  Germ layer gene expression analysis.  Germ layer differentiation was 
initiated at day 0.  (A-D) RNA was prepared from cells harvested at day 0 (hESCs) 
or day 6 and analyzed for genes characteristic of pluripotency (A), endoderm (B), 
mesoderm (C), or ectoderm (D) by qPCR.  Expression was normalized to the 
housekeeping gene GAPDH and all values are relative to hESC expression at day 0.  
Error bars represent mean ± SD of 3 pooled wells from a single plate assay. 
A 
B 
C 
D 
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3.3.3 96-well growth factor screening assay 
 We next sought to apply the 96-well flow cytometry assay to efficiently screen 
specific growth factors across a range of concentrations.  The concentrations of 3 growth 
factors, activin A (0-100 ng/mL), BMP4 (0-40 ng/mL), and VEGF (± 10 ng/mL), were 
assessed for differentiation to endoderm and mesoderm over the course of 6 days.  The 
expression of PDGFRa was assessed for an additional mesodermal marker and to 
indicate early progression towards the paraxial germ layer [43].  As discussed previously, 
SSEA3+, CXCR4+KDR-, and KDR+SSEA-3- expression was used to indicate 
undifferentiated cells and commitment of cells to endoderm and mesoderm, respectively.  
As expected, expression of the pluripotency marker, SSEA-3, steadily decreased in 
conditions with increasing concentrations of activin and BMP4 (Fig. 3.8A).  
CXCR4+KDR- expression was nonexistent in the absence of activin A, whereas a low 
concentration of activin A (10 ng/mL) was sufficient to induce high (>60% of cells) 
CXCR4 expression (Fig. 3.8B).  Increasing activin A from 10 to 100 ng/mL increased 
CXCR4+KDR- expression for high BMP4 conditions, but otherwise did not have a 
notable effect upon CXCR4+KDR- expression.  For a constant activin A concentration, 
increasing BMP4 consistently reduced CXCR4 expression.  PDGFRa+ and KDR+ 
populations were greatest in the absence of activin A (Fig. 3.8C-D).  Increasing the 
activin A concentration immediately abrogated PDGFRa expression.  Activin A and 
BMP4 displayed a competitive relationship upon KDR+SSEA-3- expression.  Increasing 
BMP4 concentration increased KDR expression, whereas activin A consistently inhibited 
this expression.  For most conditions, the additional supplementation of 10 ng/mL VEGF 
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had no notable effect upon the expression of this set of cell surface markers (Fig. 3.8A-
D). 
 These data suggest this 96-well flow cytometry assay can be utilized to screen for 
the effect of a spectrum of growth factor concentrations upon hESC differentiation in 
Figure 3.8.  96-well plate growth factor screening analysis.  Activin A, BMP4, and 
VEGF concentrations were varied over a 96-well plate and SSEA-3+ (A), 
CXCR4+KDR- (B), PDGFRa+ (C), and KDR+SSEA-3- (D) expression were 
analyzed using flow cytometry after 6 days of differentiation.  All samples 
contained bFGF (days 1-4: 2.5 ng/mL; days 4-6: 5 ng/mL).  VEGF concentration 
was ± 10 ng/mL. (A) Pluripotency decreased with increasing activin A and BMP4.  
(B) Endoderm populations increased with increasing activin A and decreased with 
increasing BMP4.  (C-D) Mesoderm character was highest in the absence of activin 
A. PDGFRa+ mesoderm was only detectable with no activin.  KDR+SSEA-3- 
mesoderm populations consistently increased with increasing BMP4 concentration 
and decreasing activin A concentration.  All concentrations are ng/mL.  Error bars 
represent the mean of 2 wells ± SD from a single plate assay. 
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serum-free conditions.  Furthermore, increased concentrations of both activin A and 
BMP4 reduce pluripotency.  Increasing activin A concentration increases CXCR4+KDR- 
endoderm populations and reduces both KDR+SSEA-3- and PDGFRa+ mesoderm 
populations.  Conversely, increasing BMP4 concentration increases KDR+SSEA-3- 
mesoderm populations but decreases CXCR4+KDR- endoderm populations. 
 
3.3.4 Tracking germ layer differentiation through gene expression kinetics 
 Kinetic analyses can also be performed during the differentiation assays.  By 
keeping BMP-4 constant at 10 ng/ml, 4 of the previously screened induction conditions 
were chosen in which 2 were optimal for endoderm (activin A at 20 ng/ml ± 10 ng/mL 
VEGF) and 2 were optimal for mesoderm (activin A at 0 ng/ml ± 10 ng/mL VEGF).  All 
conditions were carried out on a single 96-well plate.  Gene expression profiles were 
determined from cells obtained during the six days of differentiation.  Genes expressed 
during mesoderm and endoderm induction were analyzed, with the inclusion of OCT4 as 
a marker of pluripotency in undifferentiated cells. 
 Mesoderm genes (KDR, PDGFRa, MEOX1, CD34) were consistently expressed 
at higher levels in the absence of activin A while endoderm genes (FOXA2, CXCR4, 
SOX17) were consistently expressed in the presence of activin A (Fig. 3.9).  OCT4 
expression steadily decreased in all conditions over the 6 day period.  Brachyury 
expression peaked rapidly at days 2-4 and then decreased in all samples, indicative of 
ESCs passing through the primitive streak stage [9, 53, 54].  Additionally, non-activin A 
conditions demonstrated a clear progression through a Brachyury+KDR- stage to a 
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Brachyury+KDR+ stage, indicative of pre-mesoderm to mesoderm/hemangioblast 
differentiation [42, 53].  PDGFRa is a marker of mesendoderm [55] and was expressed 
in all samples at day 4 followed by increased expression in mesoderm inducing 
conditions.  CXCR4, while expressed 100 fold higher in the activin A conditions, was still 
upregulated 10-fold in the absence of activin A when compared to undifferentiated cells.  
This is to be expected since CXCR4 is not entirely endoderm specific but is also 
Figure 3.9.  Gene expression kinetic analysis.  4 conditions (10 ng/mL BMP4, ± 20 
ng/mL activin A, ± 10 ng/mL VEGF) were chosen from the results of the growth 
factor screening experiment (Fig. 4) and analyzed for transcript expression levels 
during the 6-day differentiation procedure.  Pluripotency (OCT4) decreased over 
differentiation and Brachyury expression peaked between 2-4 days.  Endoderm 
genes (FOXA2, CXCR4, SOX17) were expressed much higher for conditions 
supplemented with activin A, whereas mesoderm gene expression (KDR, PDGFRa, 
MEOX1, CD34) was highest for non-activin A conditions.  VEGF increased CD34 
and decreased PDGFRa expression at late time-points.  Expression was normalized 
to the housekeeping gene GAPDH and all values are relative to hESC expression at 
day 0.  Error bars represent mean ± SD of 3 pooled wells from a single plate assay. 
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expressed by migrating mesoderm [41].  This result is consistent with CXCR4 protein 
expression detected by flow cytometry (Fig. 3.3A).  Generally, the addition of VEGF had 
no notable effect upon gene expression, with the exception of lateral (CD34) and paraxial 
(PDGFRa) specific genes.  The expression of CD34, a lateral mesoderm and 
hematopoietic cell marker, was induced in the absence of activin A but only in the 
presence of VEGF.  Conversely, the expression of the paraxial gene, PDGFRa, was 
highest in the abscence of activin and VEGF, indicating that VEGF drives lateral or 
hematopoietic differentiation [43].  
 
3.3.5 siRNA knockdown during endoderm differentiation 
 In addition to the amount of information that can be derived using this 96-well 
format in optimizing growth factor conditions and kinetics, this format is ideal as a high 
throughput siRNA screening platform during the differentiation of hESCs.  To verify that 
siRNA knockdown can be achieved in this 96-well format without disrupting 
differentiation, hESCs that constitutively express an RFP protein [30] were utilized.  
These cells were induced to differentiate using endoderm conditions and transfected with 
a siRNA molecule targeting the RFP mRNA.  Following 6 days of differentiation, cells 
were analyzed using flow cytometry and qPCR.  Both control and mock-treated cells 
vividly fluoresced after 6 days, whereas cells exposed to the siRFP molecule only 
expressed very low levels of fluorescence (Fig. 3.10A).  To evaluate RFP protein 
expression during endoderm induction, both RFP and CXCR4 expression were analyzed 
using flow cytometry (Fig. 3.10B).  Approximately 85% of both the control cells and 
cells transfected with scrambled siRNA were RFP+, compared to 4% of the cells 
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transfected with siRNA targeted to RFP.  In all conditions, 75-80% of the cells in all 
conditions were CXCR4+, with no notable decrease caused by siRFP knockdown.  To 
further verify that siRNA knockdown had not altered endoderm differentiation, qPCR 
analysis was performed after 6 days of differentiation (Fig. 3.10C) to analyze RFP 
expression and the anterior primitive streak/definitive endoderm markers FOXA2 and 
CER1.  RFP transcript expression decreased by 96% as a result of siRNA knockdown.  
Neither FOXA2 nor CER1 expression were notably influenced by siRNA knockdown.  
These data suggest that siRNA knockdown can be performed in a 96-well format without 
significantly altering targeted differentiation. 
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Figure 3.10.  siRNA-mediated RFP knockdown during endoderm differentiation.  
hESCs were reverse transfected with siRFP or a scrambled control when seeded 
into 96-well plate format and induced to form endoderm in high activin A SFD 
media.  (A): Fluorescence microscopy of day 6 EBs.  (B) Flow cytometry of day 6 
cells showing RFP (y-axis) vs. CXCR4 (x-axis) expression.  CXCR4 expression 
was not diminished by siRNA-induced RFP knockdown.  (C) Gene expression 
analysis.  qPCR was performed at day 6 to analyze RFP transcript expression as 
well as the endoderm genes FOXA2 and CER1.  RFP knockdown had no notable 
effect upon endoderm differentiation.  Error bars represent mean ± SD of 3 pooled 
wells from a single plate assay. 
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3.4 Discussion 
 Serum-free and feeder-free hESCs differentiation protocols are essential in order 
to 1) maximize experimental control and reproducibility and 2) develop clinically 
applicable regenerative therapies [56].  Many studies have focused on titrating growth 
factors and inhibitors within SFD cocktails to optimize target cell differentiation.  As 
lineages are further explored, the possible combinations of factors will inevitably rise.  
Screening assays are extremely effective in this pursuit.  We have developed a high 
throughput, multicolor flow cytometry assay of hESC differentiation that can be utilized 
to assess a range of SFD conditions.  This small scale format requires approximately 92% 
less reagents and growth factors than 6-well culture conditions and occupies 6% of the 
incubator space.  Additionally, this assay utilizes surface markers to allow for live-cell 
analysis and sorting. 
  We differentiated hESCs to the three primary germ layers in this system, 
identified extracellular biomarker profiles for each, and confirmed germ layer identity 
with gene expression analysis.  A wide variety of extra- and intracellular markers have 
been previously utilized to identify each of the primary germ layers.  Given the 
heterogeneous expression patterns of endoderm, mesoderm, and ectoderm, no four-
marker combination will perfectly distinguish all cells within each lineage.  CXCR4 is 
expressed in migrating early endoderm and mesoderm [41], developing vascular 
endothelial cells [57], as well as migrating neural stem cells [58].  Although typically 20-
25% of mesodermal cells expressed CXCR4, our results showed that endoderm was 
uniquely distinguishable by CXCR4+KDR- expression at this stage of differentiation.  
KDR is expressed on mesoderm cells after exiting the primitive streak [59] and has been 
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utilized to characterize hESC differentiation to general mesoderm as well as vascular and 
cardiac progenitors [42, 43, 60].  Although our results corresponded with previous studies 
that have found KDR expression in a portion of hESCs [39], mesodermal cells generated 
by high BMP4 conditions were uniquely identifiable by KDR+SSEA-3- expression.  
Currently, no well-characterized extracellular early ectoderm surface markers have been 
validated.  Ectoderm has typically been characterized by the intracellular markers Nestin, 
b-III Tubulin, or Sox1 [51, 61-65].  We exploited the delayed expression of SSEA-3 into 
the early neural stem cell stage [46] to overcome the confounding NCAM expression in 
endoderm and mesoderm.  Transcript expression indicated that this stage is similar to the 
primitive anterior neuroectoderm/neuroepithelia stage defined by Pankratz et al. [66], 
namely that PAX6 expression is upregulated with SOX1 expression beginning to 
increase.  This strategy carries the caveat that SSEA-3+NCAM+ phenotyping would not 
be applicable at a later stage in the ectoderm lineage due to the loss of SSEA-3 
expression. 
 Although exact comparisons are difficult to make due to various time points, 
markers utilized, data reported, and host species differences, we obtained excellent yields 
in relation to previous studies.  Serum-containing, high activin A protocols have 
produced SOX17+ endoderm yields ranging from 55% [28] to greater than 80% [67] after 
5-6 days of differentiation in hESCs.  Our yield of 80% for H9 cells falls within the 
higher range of this spectrum.  Day 6 KDR+ mesoderm populations 15-25% [68] and 
52% [69] cells have been obtained from hESCs.  We obtained greater than 74% 
KDR+SSEA-3- mesoderm yields for multiple hESC lines.  Patani et al. generated day 4 
and day 8 yields of 51% and approximately 80%, respectively, for cells positive for the 
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neuroectoderm marker MUSASHI from hESCs [70].  Chambers et al. generated greater 
than 80% HES5+ neuroectoderm after 11 days of hESC differentiation [50].  Our 6 day 
protocol generated yields of 41-57%, comparable to these studies given the shorter time 
duration. 
 Many cytokine conditions, small molecules, and transfection conditions may 
induce cellular toxicity.  Additionally, seeding densities may be highly variable due to the 
inability to seed hESCs as single cell suspensions in many lines.  It is vital to obtain 
consistent and reliable results from a screening assay despite these caveats.  This small-
scale culture system demonstrated remarkable inter-well repeatability and density-
robustness, particularly since static EB differentiation systems have been reported to 
generate highly heterogeneous cell populations [11].  Since 96- and 384-plate assays can 
display variations due to edges, evaporation, thermal variations, and pipetting error [71-
73], we utilized gas permeable membranes and stainless steel lids to minimize 
evaporation and ensure a uniform heat distribution[74].  All standard deviations were less 
than 4% for biomarker signals, which allowed for highly significant differences between 
conditions. 
 While many studies have utilized siRNA as a tool for studying ESC 
differentiation, there is limited data reporting the presence or absence of off-target siRNA 
effects upon differentiation outcome.  Non-viral transfection of off-target siRNA 
molecules has been found to induce adipogenesis in human mesenchymal stem cells [75].  
Hence, it is important to measure the effects that transfection or transduction may induce 
in ESC differentiation protocols.  We found that siRNA-mediated knockdown of 
constitutively expressed RFP was highly efficient and induced no notable effects upon 
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endoderm differentiation.  Cells were transfected with the siRNA molecules at Day 1 of 
differentiation and exhibited significant RFP knockdown at Day 6.  This assay provides a 
siRNA screening platform that can potentially be utilized for differentiation pathway 
analysis. 
 In an effort to demonstrate the efficiency and power of this 96-well assay system, 
we conducted a growth factor screening assay utilizing a single 96-well plate and 
analyzed 32 conditions in duplicate.  We then extended the capabilities of this small-scale 
system to analyze time-course gene expression profiles for four of these conditions, 
again, within a single 96-well plate.  bFGF in combination with activin A or BMP4 drove 
differentiation and reduced pluripotency.  In particular, the greatest number of 
CXCR4+KDR- cells was induced by low to high activin A with no BMP4.  Gene profiles 
over the 6 day time period for the activin A + BMP4 conditions confirmed that these 
CXCR4+KDR- cells were characteristic of definitive endoderm.  These results correspond 
to previous studies that found increased CXCR4 expression and increased definitive 
endoderm yields by differentiating cells in high activin A containing SFD conditions [67, 
76].  Our results are similar to those of Vallier et al. in which high activin A in 
combination with bFGF and BMP4 induced mesendoderm [51].  Several studies have 
previously reported that activin A + bFGF blocks differentiation and maintains 
pluripotency [51, 77], whereas our results demonstrated increased endoderm production.  
Our protocol includes a BMP4 exposure step at day 0-1 to serve as a “jumpstart” to 
differentiation.  The decrease in pluripotent marker expression in subsequent activin A + 
bFGF SFD conditions is likely attributable to this step.  Activin A and BMP4 exhibited a 
competitive effect upon mesoderm marker expression.  The presence of activin A alone 
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eliminated PDGFRa expression at day 6, although all samples demonstrated transcript 
expression through the day 2-4 primitive streak stage.  This PDGFRa reducing effect of 
activin A has been previously observed [51].  Similarly, activin A reduced KDR+SSEA-3- 
expression, with highest expression levels seen in high BMP4 SFD conditions with no 
activin A.  These results also corroborate previous studies that have induced mesoderm 
and vascular progenitors through BMP4 activation [33, 78] and noted reduced KDR 
expression with increasing activin A supplementation [39, 42, 51]. 
 The addition of VEGF to SFD had no notable effect upon surface marker 
expression at day 6.  However, CD34 transcript expression increased and PDGFRa 
expression decreased, indicating a role in inducing early mesoderm cells towards a 
hematopoietic lineage.  Indeed, several studies have utilized VEGF to induce 
mesendoderm or mesoderm progenitors towards a hematopoietic or cardiovascular state 
[24, 39, 79], and VEGF inclusion has been shown to improve subsequent hematopoietic 
blast colony formation [42]. 
 Elucidating the optimal serum-free protocols for EB differentiation of hESCs will 
require exploring a vast combinatorial field of growth factors, inhibitors, and cytokines.  
This small scale culture platform and live-cell flow assay provides a more efficient and 
more cost-effective approach to analyzing a large number of conditions.  It can 
additionally be utilized to discover biological pathways or optimize differentiation 
through RNAi or miRNA screens.  By varying biomarkers, this assay can be adopted to 
various stages of lineage differentiation to significantly enhance progress towards hESC-
derived clinical therapies.   
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4. Optimizing Hematopoietic Differentiation 
4.1 Abstract 
 An in vitro method of generating functional hematopoietic cells would alleviate 
the strain on the limited availability of donor-supplied cells caused by the widespread 
prevalence of hematopoietic malignancies.  Embryonic stem cells offer hematopoietic 
generating potential, but reported protocols are either not clinically translatable or 
inefficient.  Additionally, a reliable, defined protocol would allow controversial and 
unknown nuances of human embryonic hematopoiesis to be resolved.  We have applied a 
high throughput hESC differentiation assay to both study hematopoietic differentiation 
and optimize the generation of primitive hematopoietic progenitor cells.  Specifically, we 
performed numerous cytokine and inhibitor screens to develop a stepwise protocol that 
utilizes serum-free differentiation medium supplemented with defined concentrations of 
growth factors BMP4, VEGF, bFGF, TPO, and IL-3 and the kinase inhibitors Y-27632 
and Chir-99021 to generate CD43+CD41+CD235+ primitive megakaryocyte-
erythromyeloid progenitors and CD41+CD42+ megakaryocytes after 8 and 11 days of 
embryoid body differentiation, respectively.  We obtain approximately 1 day 8 progenitor 
and 1 day 11 megakaryocyte for every 2 initial hESCs.  This highly efficient 
differentiation protocol will allow a greater understand of primitive hematopoietic 
differentiation. 
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4.2  Introduction 
4.2.1 Primitive hematopoiesis 
 Embryogenesis is characterized by two waves of erythrocyte production.  The 
initial wave, primitive hematopoiesis, occurs in the extraembryonic yolk sac between 
embryonic days 7.25 and 9 (E7.25-9) in the murine embryo [80].  This stage is primarily 
characterized by the production of transient, large, nucleated “primitive” erythrocytes that 
express embryonic globin (e-globin) but not adult globin (b-globin).  The second wave, 
definitive hematopoiesis, begins around E9.5 within the embryo proper, continues 
throughout post-natal life, and is characterized by the production of enucleated, adult 
globin-expressing erythrocytes, as well as all adult hematopoietic cells [81]. 
 Primitive hematopoiesis remains an incompletely understood phenomenon, 
particularly in humans in which in vivo are essentially not possible.  The hallmark of this 
process is the production of a hemangioblast, a progenitor cell with both erythrocytic and 
endothelial potential.  The hemangioblast first originates in the most posterior region of 
the primitive streak prior to migrating to the extraembryonic yolk sac [82].  Studies have 
also demonstrated myeloid [80] and megakaryocyte [83] potential from early yolk-sac 
derived cells, indicating that hemangioblasts can differentiate to these lineages as well.  
Although the exact transition from primitive to definitive hematopoiesis is debated, 
primitive erythrocytes have disappeared by E9, around the time of definitive onset.  
Multipotent progenitors have been found in the yolk sac at E8.5 [84], and hematopoietic 
stem cells (HSCs) with long term engraftment potential have been found in the embryo 
proper by E10.5 [85].  
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 Due to ethical and practical difficulties, far less is understood regarding 
hematopoiesis in the human embryo. Much of the knowledge of the hemangioblast and 
primitive hematopoiesis has now come from ESC studies.  Kennedy et al. found that a 
progenitor cell with erythrocytic, macrophage, and endothelial differentiation potential 
arose within a KDR+ population after 7 days of differentiation [19].  Klimchenko et al. 
proved the emergence of a primitive megakaryocyte-erythroid progenitor arising after 9 
days of differentiation that could generate primitive erythrocytes and a primitive form of 
megakaryocyte whose ploidy remained typically less than 8N [86]. 
 Inducing definitive hematopoiesis in ESC studies has proven much more elusive.  
An unknown mechanism must occur to “mature” hematopoietic progenitor cells from 
primitive to definitive.  This mechanism has so far been provided either by feeder cells or 
by serum supplementation.  Co-culture of mESCs upon an OP9 murine stromal layer, 
characterized by its inability to produce macrophage colony-stimulating factor (M-CSF), 
induces differentiation of all hematopoietic lineages [87].  Co-culture upon OP9 cells 
along with forced expression of definitive gene HoxB4 induces a definitive HSC capable 
of long-term engraftment in adult mice [17, 20].  Undirected EB differentiation in serum-
containing medium induces two sequential waves of primitive followed by definitive 
hematopoiesis [18].  Exact pathways involved in these systems have yet to be 
determined. 
 
4.2.2 In vitro hematopoietic hESC systems 
 Due to the paucity of available HSCs for clinical therapies, there is a large need 
for in vitro protocols that can reliably produce functional HSCs capable of engraftment in 
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humans.  In vitro systems also offer the ability to study developmental mechanisms in a 
controllable environment.  Vodyanik et al. developed an OP9 bone marrow stromal line 
coculture system and studied the progression of hESC hematopoietic differentiation [88].  
They generated CD34+ primitive hematopoietic cells after 8-9 days of differentiation 
capable of generating primitive erythroid, megakaryocytic, and myeloid colonies.  
Additionally, after further coculture on MS-5 stromal cells, these cells produced myeloid 
and select lymphoid cells.  After further study, it was determined that the CD43+ 
subpopulation of CD34+ cells generated with this system differentiated committed 
hematopoietic progenitors from endothelial and mesenchymal cells [89].  While these 
systems shed light on hematopoietic differentiation of hESCs, coculture with animal cells 
prohibits translating protocols to the clinic.  Furthermore, due to the unknown factors 
produced by feeder layers, a thorough understanding of requisite signaling cues was not 
possible. 
 The feeder-free methylcellulose EB differentiation system developed by Zambidis 
et al. demonstrated a wave or primitive hematopoietic progenitors characterized by 
CD34+CD31+ expression and a second definitive wave from CD45+ cells [18].  While 
shedding light on hematopoiesis of hESCs, the use of serum in this system still presented 
a need for serum-free systems to be created. 
 Several studies have developed serum-free hESC hematopoietic differentiation 
systems, although hematopoietic progenitor yields have been modest.  Pick et al. assessed 
combinations of cytokines to optimize hematopoietic differentiation and obtained a 16% 
yield after 10 days of differentiation [24].  Chicha et al. utilized an EB based system to 
produce CD34+ cells after 8 days capable primitive erythroid and myeloid colony 
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forming ability.  Up to 20% of total day 8 cells expressed CD34, although no reference to 
initial seeding density was made [90].  Niwa et al. utilized a stepwise procedure to induce 
KDR+CD34+ progenitors, representing less than 10% of total cell population after 6 days 
of differentiation [91]. 
 For clinical translation, protocols will need to generate large quantities of target 
hematopoietic cells.  This represents a need for high yielding differentiation protocols.  
The lack of an efficient serum-free EB protocol to generate hematopoietic progenitors 
motivated us to apply the EB differentiation screen to optimize hematopoietic 
differentiation of hESCs.  Furthermore, we sought to establish a stepwise protocol to 
generate megakaryocytes in suspension culture. 
 
4.3 Results 
4.3.1 VEGF hematopoietic differentiation screen 
 Having established conditions to optimize the differentiation of KDR+ mesoderm 
cells [92], we initially aimed to investigate inducing cells further down the hematopoietic 
lineage.  Although VEGF had no effect upon KDR+ expression in our system, it did 
induce higher CD34 transcript expression and has been demonstrated to be requisite for 
hematopoietic differentiation of ESCs [42].  While previous results had demonstrated the 
ability of BMP4 to effectively induce KDR+ mesoderm, we also sought to explore its 
relationship upon inducing hematopoietic cells.  Therefore, we performed an EB 
differentiation screen by supplementing with 0-40 ng/mL BMP4 and 0-100 ng/mL 
VEGF.  bFGF was supplemented at 5 ng/mL from days 3-6 (Fig. 4.1A).  As opposed to 
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prior experiments, BMP4 was removed at day 3 to avoid the differentiation towards 
trophoblast and extraembryonic endoderm caused by long term exposure [69]. The pan-
hematopoietic marker CD34 and the hemato-endothelial marker CD31 are the first 
hematopoietic markers expressed during OP co-culture of hESCs [88] and were thus 
assessed by flow cytometry after 6 days of differentiation. 
 
Figure 4.1.  VEGF and BMP4 hematopoiesis screen.  (A) Schematic of the 6-day 
differentiation screen with growth factor concentrations.  Medium was replaced after 3 
days of differentiation. (B) Representative flow cytometry plot of conditions inducing 
CD34+CD31+ cells. (C) Percentage of CD34+CD31+ cells for the assayed BMP4 and 
VEGF conditions.  Results are given as percentages of total cells within each 
condition.  (D) Cell viability for the assayed conditions.  Bars represent the mean ± SD 
of two wells. 
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 Both markers were expressed at approximately the same rates in cells, as 
demonstrated by the double positive population in Figure 4.1B.  Hematopoietic character 
was proportional to the concentration of VEGF in the differentiation medium (Fig. 4.1C).  
Conditions lacking VEGF induced roughly 10% of cells toward the hematopoietic 
lineage.  Increasing concentrations steadily induced higher percentages of total day 6 
CD34+CD31+ cells, with approximately 40% of cells in 100 ng/mL VEGF medium 
expressing both markers.  There was no clear relationship between BMP concentration 
and early hematopoietic character. 
 In contrast to general mesoderm conditions from previous experiments, 
hematopoietic differentiation conditions were characterized by low and highly variable 
viability (Fig. 4.1C).  Viability generally increased with increasing concentrations of 
VEGF.  BMP4, conversely, induced lower cell counts, although trends were not 
consistent.  These data suggest that the 96-well assay could be utilized to screen 
hematopoietic differentiation conditions.  Additionally, VEGF supplementation 
concentration is proportional to the percentage of cells characteristic of early 
hematopoietic cells and induces higher viability after 6 days of differentiation.  
Increasing BMP4 concentrations tends to result in lower viability. 
 
4.3.2 Hematopoietic differentiation in 96-well format 
 Having established the capability and basic conditions for early hematopoietic 
differentiation in 96-well format, we next sought to explore cell phenotype over a longer 
period of differentiation.  Cells were seeded into 96-well plates at day 0 with 25 ng/mL 
BMP4 and 50 ng/mL VEGF, and medium supplemented with 5 ng/mL bFGF was added 
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at days 2 and 6 (Fig. 4.2A-B).  In an effort to increase viability following differentiation, 
the Rho-associated protein kinase (ROCK) inhibitor Y-27632 was added to differentation 
medium for the first 48 hours [93].  EBs were dissociated and various hematopoietic 
markers were assayed by flow cytometry at days 4 and 8. 
 After 4 days of differentiation, EBs ranged in size from 50-300 mM in diameter 
(Fig. 4.2D).  A distinct KDR+CD31+CD34+ population of cells had emerged (Fig 4.2C).  
These cells were absent of CD43 and CD41 expression.  Most cells were KDR+ and 33% 
± 3% had begun expressing CD34.  As observed previously, CD34+ cells typically 
expressed CD31 as well.  Few cells had begun to express the pan-hematopoietic marker 
CD43 or the erythrocytic marker CD235a.  Essentially all CD31+ cells were also KDR+ 
(Fig. 4.2C).  CD31 expression was preceded by KDR+ expression by about 24 hours (data 
not shown). 
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Figure 4.2.  96-well hematopoietic differentiation setup and day 4.  (A) Schematic 
of 8 day hematopoietic differentiation.  (B) Cells at Day 0 after seeding in 
suspension into 96-well format.  Scalebar, 1000 mM.  (C) Day 4 flow cytometry 
profiles demonstrating the KDR+CD31+CD34+ population.  (D) Day 4 EBs.  (E) 
Day 4 hematopoietic marker profiles.  Bars represent mean ± SD of 3 wells. 
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 After 8 days of differentiation, EBs had adopted a much larger cystic, vacuolated  
morphology with some EBs measuring 400 mM in diameter (Fig.4.3A).  EBs also 
appeared to be emitting single cells in suspension.  While the KDR+CD31+CD34+ 
population was still present, a small CD43+CD31+KDRlow/- population had emerged (Fig. 
A B 
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Figure 4.3.  Day 8 hematopoietic cells.  (A) Day 8 EBs. (B) Day 8 hematopoietic 
marker profiles.  Bars represent mean ± SD of 3 wells.  (C) Day 8 flow cytometry 
profiles.  Cells within the gated CD31+CD43+ population in the upper left plot are 
highlighted in green in remaining plots. 
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4.3C).  These cells also expressed CD235a and the megakaryocytic marker CD41 and 
were CD34+/-.  This population only represented approximately 3% of total cells. 
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C 
Figure 4.4.  Day 8 separated EBs and single cells.  (A) Day 8 flow cytometry 
profiles.  (B) CD31, CD43 expression for EB cells.  (C) Flow cytometry plots for 
single cells demonstrating CD43, CD41, and CD235a expression.  (D) Cell viability 
over 8 days of differentiation. 
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 It was hypothesized that this CD43+ population consisted of single cells released 
from EBs.  In order to evaluate this possibility, wells were pooled and EBs were allowed 
to settle for several minutes.  The supernatant was then withdrawn, EBs were dissociated, 
and flow cytometry was performed on both sets of cells.  EBs exhibited almost no 
expression of the hematopoietic markers CD43, CD41, and CD235a, whereas more than 
90% of single cells expressed CD43 (Fig. 4.4A-C).  Approximately 20% of single cells 
had also begun expressing the committed megakaryocytic marker CD42a. 
 Cell viability immediately decreased following seeding at Day 0.  Day 4 
populations were still less than 40% of the initial number of hESCs seeded (Fig. 4.4D).  
Yield had grown to higher than 50% at day 8, although the magnitude of single cells was 
lower than 500 cells/well, representing less than a 2.5% yield. 
 This data suggests that as hematopoietic differentiation proceeds, an early 
population of KDR+CD31+CD34+ cells is generated by day 4 and gives rise to a 
CD31+CD43+CD41+CD235a+ population by day 8.  This day 8 population emerges 
predominantly as single cells released by EBs.  Although not shown, a very small amount 
of these cells (several cells per well) was observed at day 6. 
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 In order to characterize the hematopoietic potential of the day 7-8 single cells and 
verify the scalability of this system, hESCs were differentiated in identical conditions in 
6-well culture format.  Single cells were isolated after 7 days of differentiation and 
seeded into methycellulose and supplemented with hematopoietic cytokines to test colony 
forming potential (Fig. 4.5).  At day 7, heterogenous EBs and single cells were both 
visible in cultures (Fig. 4.6A).  Over 90% of single cells were CD43+CD31+ (Fig. 4.6B).  
41% were CD41+CD235a+, with some cells already expressing single lineage markers.  
Cells were KDRlow/- and approximately 70% were CD34-.  Approximately 10% of cells 
expressed a CD41-CD34+ phenotype. 
Figure 4.5.  Schematic of 6-well scaled up procedure and single cell progenitor 
assays.  Single cells were isolated at day 7 of differentiation and either cultured in 
methylcellulose for CFC analysis or re-suspended in differentiation medium 
supplemented with various cytokines to monitor differentiation progression. 
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 After 12 days of methylcellulose culture, cells had given rise to colonies of 
primitive erythrocytic, macrophage, and mixed morphology (Fig. 4.7A, B).  Cytospins 
and May-Grunwald-Giemsa staining were then performed on selected colonies and 
demonstrated primarily primitive erythroblast and macrophage cells.  These results 
suggest that differentiation conditions identified by the 96-well assay are scalable to 6-
well plate or larger formats and that single cells produced after 7 days of differentiation 
have erythromyeloid potential. 
Figure 4.6.  Phenotype of day 7 cells.  (A) Day 7 EBs and single cells.  Scalebar, 
400 mM.  (B) Flow cytometric marker profiles of day 7 single cells. 
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 Differentiating day 7 suspension single cells for a further 4 days in hematopoietic 
medium (containing SCF, TPO, EPO, Flt3-L, IL-6, and IL-3) produced cells 
morphologically characteristic of blast cells, primitive erythrocytes, and myeloid cells 
(Fig. 4.8A).  At least three distinct populations were evident based off of marker 
expression profiles (Fig. 4.8B).  A CD41highCD42a+CD235a-CD43high population 
indicated the presence of committed megakaryocytes (approximately 25% of cells).  A 
CD235a+CD41-CD43mid/low population indicated committed erythrocytes.  A separate 
CD41low/-CD235a-CD43high/midCD31high/midKDRmid population also existed, although it 
was not clear what these represented.  Almost all cells were CD34- and slight CD18 and 
CD45 expression indicated progression towards myeloid lineages.  This suggests that day 
7 single cells are capable of further differentiating down the erythroid, megakaryocytic, 
and myeloid lineages. 
Figure 4.7.  Hematopoietic colony potential of isolated day 7 single cells.  (A) 
Colonies observed after 12 days of methycellulose culture and corresponding 
cytospins demonstrating primitive erythroblasts and macrophages.  EP: primitive 
erythrocyte colony; Mac: macrophage colony (B) Colony frequencies after 12 days.  
Bars represent mean ± SD of three assays. 
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 After 10 days of differentiation of isolated single cells, populations began to 
appear less distinct.  Committed CD235a+ erythroid and CD41+CD42a+/- megakaryocytic 
populations were still evident, although both had declined (Fig. 4.9B).   A new 
CD43lowCD41-CD235a- population was evident.  Myeloid populations, characterized by 
CD18 and CD45 expression, had increased.  Cytospins revealed multilineage cells 
resembling mature erythrocytes, megakaryocytes, and myeloid cells (Fig. 4.9A). These 
Figure 4.8.  Hematopoietic differentiation phenotypes of day 7 + 4 cells.  (A) 
Cytospin of day 7 suspension cells showing blast cell morphology.  (B) Flow 
cytometry marker profiles. 
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data suggest that multipotent day 7 progenitors do not continue to self-renew and produce 
new committed progeny when cultured in the utilized differentiation medium. 
  
4.3.3 Optimizing KDR+CD31+ and CD31+CD43+ differentiation 
 These experiments indicated that during EB hematopoietic differentiation of 
hESCs, cells progress first through a KDR+CD31+ stage before CD43+ primitive 
megakaryocyte-erythromyeloid progenitors are produced and that BMP4 followed by 
VEGF supplementation was required to induce CD31+ expression.  However, yields of 
CD43+ single cells remained modest. We next sought to optimize the yield of these 
populations by increasing differentiation percentages and viability. 
Figure 4.9.  Hematopoietic differentiation phenotypes of day 7 + 10 cells.  (A) 
Cytospin of day 7 suspension cells, showing cells characteristic of erythrocytes (E), 
megakaryocytes (MK), macrophages (Mac), and neutrophils (NP).  (B) Flow 
cytometry marker profiles. 
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 During mesoderm differentiation, BMP4 activates the Wnt pathway indirectly and 
Wnt signaling is required for primitive streak and mesoderm differentiation of mESCs 
[42, 94].  However, addition of exogenous Wnt to BMP4-supplemented conditions does 
not significantly improve hematopoietic differentiation [42].  Prior to differentiation, Wnt 
supplementation  induces proliferation in undifferentiated hESCs [95].   The canonical 
WNT pathway relies on the nuclear translocation of the transcription factor b-catenin to 
the nucleus [96].  In the absence of exogenous WNT signaling, b-catenin is 
phosphorylated by the glycogen synthase kinase 3 (GSK3) and subsequently 
ubiquitinated and degraded.  The small molecule Chir-99021 (herein referred to as Chir) 
is a highly selective inhibitor of GSK3b [97].  Inhibition of GSK3 activates the WNT 
pathway by preventing the degredation of b-catenin (Fig. 4.10).  We hypothesized that 
GSK3 inhibition during concomitant BMP4 supplementation may enhance yields by 
inducing proliferation during differentiation.  Our first objective was to evaluate the 
Figure 4.10.  Simplified schematic of Chir-induced b-Catenin nuclear translocation.  
Chir inhibits phosphorylation of b-catenin by GSK3, preventing ubiquitination in 
inducing nuclear translocation and subsequent mediation of downstream genes. 
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effect of GSK3 inhibition, and consequently WNT activation, upon EB-based 
hematopoietic differentiation of hESCs. 
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B 
Figure 4.11.  KDR-CD31 profiles for Chir, BMP4, VEGF Screen.  (A) Day 6 and 8 
profiles for all conditions.  The double positive population is clear at day 6 and the 
CD31+KDRlow/- population is evident at day 8.  (B) Time-course flow plots over 8 days 
of differentiation for medium supplemented with 2 mM Chir and 0 ng/mL BMP4. 
A 
   63 
 We performed a screen to evaluate the effects of Chir supplementation upon a 
range of BMP4 and VEGF concentrations.  hESCs were seeded at day 0 with ± Chir in 
conditions supplemented with 0-40 ng/mL BMP4 and 0-100 ng/mL VEGF.  Chir was 
removed after 48 hours by replacement with bFGF-containing medium.  After 6 days of 
differentiation, the KDR+CD31+ early hematopoietic population was observed in all 
VEGF and BMP4 containing conditions, as expected, and additionally in the Chir-
supplemented conditions with 0 ng/mL BMP4 (Fig. 4.11A).  CD31+KDRlow/- cells were 
evident in all VEGF and BMP4-containing conditions at day 8 and in Chir-exposed 
conditions without BMP4.  Additionally, in Chir-conditions, this population surprisingly 
declined with increasing BMP4 concentrations.  Smaller populations of these cells were 
also observed in wells containing both Chir and BMP4.  Time course flow cytometry 
demonstrated that CD31+ expression was delayed by up to 2 days by replacing BMP4 
with Chir (Fig. 4.11B).  Chir also greatly enhanced post-seeding cell viability, 
particularly in the absence of BMP4 (data not shown).  This observation indicated that 
Chir supplementation may compliment or replace BMP4 supplementation and may 
enhance viability.  Smaller CD31+KDRlow/- for increasing BMP4 concentrations in Chir-
exposed conditions indicated that higher concentrations of BMP4 may inhibit 
hematopoietic differentiation. 
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Figure 4.12.  Day 3 results of the hematopoietic screen with Chir.  (A) Experiment 
schematic (B) Images of EBs for the three conditions, all with 2.5 ng/mL BMP4.  
Scalebar, 1000 mM.  (C) KDR, SSEA3 flow cytometry profiles of conditions.  (D) 
Flow cytometry marker expression profiles.  Expression values are given as percent 
of total live cells.  Bars represent the mean ± SD of 4 wells.  B-D0-3: BMP4 
supplementation from Days 0-3.  Chir concentration was 2 mM. 
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 To evaluate these possibilities, a repeat screen was performed upon BMP4 
concentrations of 0-10 ng/mL.  Unlike the previous experiment, Chir was replaced with 
bFGF containing medium at day 1.  BMP4 was supplemented for either days 0-3 or days 
1-3 (Fig 4.12A).  After 3 days and throughout differentiation, EBs in Chir-containing 
conditions were more defined and exhibited less surrounding apoptotic cells (Fig 4.12B).  
After 3 days of differentiation, Chir notably induced greater differentiation, as evidenced 
by lower SSEA3 expression (Fig 4.12C).  Dual BMP4 and Chir supplementation induced 
the early mesoderm KDR+ population, whereas this population had yet to emerge in 
conditions without Chir.  A smaller KDR+ population was evident in conditions without 
BMP4 for the first 24 hours.  In Chir-containing conditions, KDR expression was 
proportional to the concentration of BMP4, with over 80% of cells KDR+ when 
supplemented with Chir and 10 ng/mL BMP4. 
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 After 5 days of differentiation, Chir EBs continued to remain larger than BMP4 
alone EBs (Fig. 4.13A).  Postponing BMP4 supplementation by 24 hours resulted in 
smaller EBs.  BMP4-containing conditions displayed similar KDR+CD31+ populations, 
Figure 4.13.  Day 5 results of the hematopoietic screen with Chir.  (A) Images of 
EBs for the three conditions, all with 2.5 ng/mL BMP4.  Scalebar, 1000 mM.  (B) 
CD31, KDR flow cytometry profiles of conditions.  (C) SSEA3+ and 
CD31+KDR+marker expression profiles.  Expression values are given as percent of 
total live cells.  Bars represent the mean ± SD of 4 wells.  Day 0 cell seeding 
density is represented by the red dashed line.  Chir concentration was 2 mM.  B-D0-
3: BMP4 supplementation from Days 0-3. 
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with efficiencies generally ranging 50-65% (Fig. 4.13B, C).  This population appeared to 
plateau for BMP4 concentrations greater than 2.5 ng/mL.  Delaying BMP4 addition in 
small concentrations by 24 hours again delayed differentiation, as noted by increased 
SSEA-3 expression and decreased CD31 expression.  Although Chir induced higher 
KDR+ populations at day 3, there was no corresponding increase in CD31+KDR+ cells at 
day 5.  Yields, however, were significantly higher for Chir containing conditions due to 
higher viability (Fig. 4.14).  Samples exposed to Chir without BMP4 for 24 hours were 
extremely variable.  For BMP4 concentrations greater than 5 ng/mL administered at day 
1, Chir supplementation increased cell counts by an average of 5-fold.  However, 
viability was similar to BMP4 alone conditions for lower concentrations.  Simultaneous 
Chir and BMP4 supplementation at day 0 increased viability by approximately 100% 
over BMP4 supplementation alone. 
Figure 4.14.  Day 5 viability.  Expression values are given as percent of total live 
cells.  Bars represent the mean ± SD of 4 wells.  Day 0 cell seeding density is 
represented by the red dashed line. 
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 As seen previously, CD43+ cells had begun to emerge by day 8, most 
predominantly in BMP4-containing conditions  EBs were typically more frequent and 
larger for Chir conditions (Fig. 4.15A).  For small concentrations of BMP4 (2.5-5 
Figure 4.15.  Day 8 results of the hematopoietic screen with Chir.  (A) Images of 
EBs for the three conditions, all with 2.5 ng/mL BMP4.  Scalebar, 1000 mM.  (B) 
CD31, CD43 flow cytometry profiles of conditions.  (C) CD31+CD43+marker 
expression profiles and cell viability.  Expression values are given as percent of 
total live cells.  Bars represent the mean ± SD of 4 wells.  Day 0 cell seeding 
density is represented by the red dashed line.  Chir concentration was 2 mM.  B-D0-
3: BMP4 supplementation from Days 0-3. 
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ng/mL), Chir enhanced CD43+ differentiation, whereas no difference in induction 
percentage was seen at 10 ng/mL (Fig. 4.15B-C).  Postponing BMP4 supplementation by 
24 hours had no significant effect upon CD43+ differentiation percentages.  In all 
samples, BMP4 concentration was proportional to the size of this population.  Although 
large variances were observed, Chir induced higher total cell viabilities than BMP4 alone 
(Fig. 4.15C).  Cell counts were generally at least double those of BMP4 alone. 
 The CD43+ populations were still present at day 11, indicating that these cells 
either remain viable over this period or are replaced by newly differentiating cells.  EBs 
were similar to day 8, although larger cystic EBs were more frequent in Chir containing 
conditions (Fig. 4.16A).  The KDR+CD31+ population was still present and relatively 
larger than day 8 for Chir conditions.  CD43 relative population sizes were generally 
similar to day 8, although the day 0 BMP4 + Chir conditions demonstrated decreases.  
Notably, Chir supplementation with no BMP4 induced a population of CD43+ cells 
unobserved at day 8 (Fig 4.16B).  Similar to day 8, viability remained increased in Chir-
containing conditions.   
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 Differentiation percentages and absolute cell counts were utilized to determine 
yields of target cells over the course of differentiation (Fig. 4.17).  In particular, we 
assessed the yields of target hematopoietic cell populations at different timepoints in 
Figure 4.16.  Day 11 results of the hematopoietic screen with Chir.  (A) Images of 
EBs for the three conditions, all with 2.5 ng/mL BMP4.  Scalebar, 1000 mM.  (B) 
CD31, CD43 flow cytometry profiles of conditions.  (C) CD31+CD43+marker 
expression profiles and cell viability.  Expression values are given as percent of 
total live cells.  Bars represent the mean ± SD of 4 wells.  Day 0 cell seeding 
density is represented by the red dashed line.  Chir concentration was 2 mM.  B-D0-
3: BMP4 supplementation from Days 0-3. 
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comparison to the initial seeding density of 20,000 cells per well.  Early hematopoietic 
populations were significantly increased for all BMP4 conditions in the presence of Chir.  
At day 3, yields were greater than 80% of cells expressing KDR when BMP4 
concentrations greater than 5 ng/mL were supplemented with Chir, compared with less 
than 5% of cells in the corresponding conditions without Chir (p<0.01).  Subsequently at 
day 5, mid-range BMP4 and Chir concentrations demonstrated approximately 75% yields 
for  KDR+CD31+, compared to less than 40% in the absence of Chir.  Similarly at day 8, 
CD43+ yields greater than 45% were observed when BMP4 concentration was at least 5 
ng/mL in the presence of Chir, compared to less than 25% in its absence.  Surprisingly, at 
day 11, conditions with Chir and no BMP4 demonstrated a yield of 34 ± 2%.   
 These results indicate that 24 hour exposure to Chir in the presence of 
concentrations of BMP4 less than 10 ng/mL enhances EB hematopoietic differentiation, 
resulting in more early-stage hematopoietic cells emerging at earlier time points.  
Additionally, Chir supplementation in the absence of BMP4 induces efficient 
hematopoietic differentiation, albeit at a delayed scale.  Initial Chir supplementation 
during hematopoietic differentiation greatly increases cell viability in 96-well format. 
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Figure 4.17.  Differentiation yields throughout 11 days of differentiation.  Yields 
are given for conditions supplemented with BMP4 from days 0-3 with and without 
2 mM Chir.  Percentages are relative to the initial day 0 seeding density of 20,000 
cells/well.  Asterisks in lower graph represent significant differences when 
compared to the corresponding condition without Chir in the top graph (*: p<0.05; 
**: p<0.01).  B-D0-3: BMP4 supplementation from Days 0-3. 
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4.3.4 Cytokine screen to enhance CD43+ progenitor differentiation and 
megakaryopoiesis 
 We established a step-wise procedure to differentiate hESCs down the 
hematopoietic lineage to obtain CD43+CD41+CD235+ cells characteristic of common 
myeloid progenitors.  This procedure demonstrated that the growth factors BMP4, VEGF, 
and bFGF were sufficient to induce this cell population.  We also found that an initial 24 
hour exposure to the GSK3b inhibitor Chir-99021 enhanced viability and hematopoietic 
differentiation.  Prior studies have shown that supplementation with various 
hematopoietic cytokines further enhances hematopoietic differentiation and is required 
for commitment to several specific lineages [86, 98, 99].  However, requirements of these 
factors to hemopoietic differentiation of hESCs in serum-free medium have not been 
assessed.  Many hematopoietic differentiation protocols of ESCs have included cytokines 
at various stages without detailing their contribution.  Additionally, reports have included 
such factors in differentiation medium and noted no apparent benefit in blast colony 
formation [100].  We sought to perform a screen of various hematopoietic cytokines to 
assess their potential enhancement to production of CD43+ progenitors and CD41+CD42+ 
megakaryocytes. 
 hESCs were differentiated according to the previously established stepwise 
protocol, including an initial 24 hour exposure to Chir-99012 (Fig. 4.18A).  At day 6, 
cells were exposed to medium supplemented with 10 ng/mL bFGF, 100 ng/mL VEGF, 
and various cytokine combinations: ± 25 ng/mL FLT3-L, ± 10 ng/mL IL-3, ± 10 ng/mL 
IL-6, and ± 50 ng/mL TPO.  Cell identity and viability were assessed at days 8 and 11.  
After 8 days of differentiation, CD31+CD43+ yields were similar amongst all conditions, 
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ranging between 40-65%, with no clear trends due to the presence or absence of different 
growth factors (Fig. 4.18B).  Viability was above the seeding density of 20,000 cells per 
well for most conditions (Fig. 4.18C). 
 
Figure 4.18.  Experiment schematic and day 8 hematopoietic cells.  (A) Schematic 
of hematopoietic cytokine screen.  (B) CD31+CD43+ populations.  Percentages 
represent percentage of total cells.  (C) Total cell viability.  Bars represent mean ± 
SD of two wells. 
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Figure 4.19.  Day 11 CD43+ hematopoietic populations.  (A) Marker profiles 
demonstrating gated CD43+CD31low/- hematopoietic cells out of total cells (left) and 
CD41 and CD235a expression for those gated cells.  (B) CD43+ populations.  
Percentages represent percentage of total cells.  (C) CD43+ percentage yields.  
Values are given as percentage of 20,000 cells/well seeded at day 0.  Bars represent 
mean ± SD of two wells. 
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 After 11 days of differentiation, cells had begun to differentiate down more 
committed lineages.  Viability was higher for cells exposed to both TPO and IL-3 (Fig. 
4.19A).  IL-6 appeared to increase viability in the absence of IL-3.  Several general 
marker expression trends were evident for all samples.  The hematopoietic progenitor 
population maintained CD43 but began to express lower CD31 expression than observed 
at day 8 (Fig. 4.19B).  A subpopulation of CD43+ cells had lost CD41 expression, 
indicating commitment to a non-megakaryocytic lineage.  Approximately one-third of 
these cells expressed CD235a, indicating differentiation toward the erythrocytic lineage.   
CD41+CD235a+ cells were still observed, although a population of CD41+ cells had lost 
CD235a expression, indicating progression towards the megakaryocytic lineage.  
Population sizes began to vary between the various cytokine conditions.  CD43+ 
differentiation percentages were increased for IL-3-containing conditions (Fig. 4.19C).  
When viability was taken into account, CD43+ yields were greater for cells exposed to 
both TPO and IL-3 and to cells exposed to both TPO and IL-6 (Fig. 4.19D).  This 
phenomenon emphasized the need to assess both marker expression percentages and 
yields.  Differences in the former imply an influence upon differentiation efficiency; in 
the latter, upon proliferation. 
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 CD41+ cells exhibited the CD31low/- phenotype (Fig. 4.20A).  Differentiation 
percentages ranged between 28-40% of total cells, with TPO and IL3 inducing more 
efficient differentiation although not significantly (Fig. 4.20B).  The greatest cell counts 
were obtained for conditions supplemented with only TPO and IL-3, with a yield of 
21,900 ± 350 cells/well, or approximately 110% of the initial hESC cell density.  When 
used in combination with TPO and IL-3, IL-6 and FLT3-L appeared to decrease yield 
slightly, but not significantly so.  Removing either TPO or IL-3 significantly reduced 
CD41+ cell generation. 
Figure 4.20.  Day 11 CD41+ hematopoietic populations.  (A) Marker profile 
demonstrating the CD41+CD31low/- population.  (B) Differentiation percentages and 
yields for total CD41+.  Percentages represent percentage of total cells (left) and 
percentages of 20,000 cells/well seeded at day 0 (right).  Bars represent mean ± SD 
of two wells. 
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 A portion of CD41+ cells had begun to express CD42a, indicating commitment to 
the megakaryocyte lineage (Fig. 4.21A).  These cells generally represented 40-50% of 
total CD41+ cells.  Due to variability, various cytokine combinations failed to significant 
affect CD42+ differentiation efficiency (Fig. 4.21B).  However, as with CD43+ and 
CD41+ cells, CD42a+ megakaryocyte yields were higher for TPO and IL-3 containing 
conditions, with TPO and IL-3 together generating a yield of 48 ± 4% (Fig. 4.21B).  
FLT3-L again appeared to inhibit CD42a+ cell production in the presence of TPO and IL-
3, although this trend was true for CD43+ hematopoietic cells in general (Fig. 4.19D).  
IL-6 appeared to inhibit CD42a expression in the presence of TPO and IL-3. 
Figure 4.21.  Day 11 CD42+ megakaryocyte populations.  (A) Marker profile 
demonstrating the CD41+CD42a+ population.  (B) Differentiation percentages and 
yields for total CD42a+.  Percentages represent percentage of total cells (left) and 
percentages of 20,000 cells/well seeded at day 0 (right).  Bars represent mean ± SD 
of two wells. 
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 These data suggest that supplementing the stepwise differentiation protocol with 
hematopoietic cytokines enhances hematopoietic progenitor generation after 11 days of 
differentiation by influencing both differentiation efficiency and cell proliferation.  More 
specifically, TPO and IL-3 increased the proportion of CD43+ cells.  These two cytokines 
also increased CD43+, CD41+, and CD42a+ yields by inducing greater proliferation 
between days 8 and 10.  For conditions containing only TPO and IL-3, CD41+ and 
CD42a+ cell yields were approximately 100% and 50%, respectively. 
 
4.4 Discussion 
 Here, we applied the 96-well EB differentiation assay to optimize distinct stages 
of hematopoietic differentiation of hESCs.  Specifically, we developed a stepwise serum-
free protocol to efficiently differentiate hESCs toward CD41+ primitive common myeloid 
progenitors and CD42+ megakaryocytes (Fig. 4.22).  Combinations of BMP4, VEGF, 
bFGF, TPO, and IL-3, along with the ROCK inhibitor Y-27632 and the GSK-3b 
inhibitorChir-99021, are utilized at distinct times during an 11 day differentiation in 
serum-free medium.  Along the procedure, cells transition from pluripotent ESCs to 
KDR+ early mesoderm, KDR+CD31+ hematopoietic cells, CD43+CD41+CD235+ 
progenitor cells, and CD41+CD42+ megakaryocytes. 
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 Initially BMP4 and Chir-99021 are utilized to push the hESCs to the primitive 
streak stage.  BMP4 has been shown to induce primitive streak differentiation and have a 
“posteriorizing effect” upon streak cells, further pushing them toward KDR+ mesoderm 
[33, 42].  In our system, BMP4 effectively induced KDR+ mesoderm and KDR+CD31+ 
mesoderm, but cell death was high, limiting the information content of endpoint flow 
cytometry results.  Wnt signalling is required for both primitive streak and KDR+ 
mesoderm formation [42, 94].  However, Wnt supplementation in addition to BMP4 has 
been shown to have little contributory effect toward either streak formation or KDR+ 
mesoderm [42].  Our results demonstrated that simultaneous Chir and BMP4 
supplementation increased viability by approximately two-fold and notably enhanced 
differentiation yields of hematopoietic cells throughout differentiation.  Chir 
supplementation prior to BMP4 exposure drastically increased cell counts in some 
conditions, consistent with the previous observation of Wnt-stimulated hESC 
proliferation [95]. 
 The exact mechanisms underlying Chir-induced enhanced primitive 
hematopoietic differentiation are unclear.   The requirement of Wnt signaling in the 
mesoderm-to-hematopoietic transition is more established.  In murine ESCs, BMP 
activates Wnt3a, which in turn promotes hematopoiesis via the Cdx-Hox pathway [101].  
Figure 4.22.  The final stepwise hematopoietic and megakaryocyte differentiation 
protocol. 
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Wnt signaling has also been shown to be required for post-mesoderm primitive but not 
definitive hematopoiesis in mESCs [42].  Our results demonstrated enhanced 
hematopoietic differentiation following an initial 24-hour activation of the Wnt pathway, 
as indicated by the action of Chir.  These results conflict with those of a previous study 
showing that Wnt treatment prior to primitive streak formation induces a mesoderm to 
cardiomyocyte route in mESCs [102].  However, these results were obtained in 
undirected, serum-containing medium, obfuscating the underlying mechanisms.  Indeed, 
human induced pluripotent stem cells (iPSCs) generated KDR+ progenitors with erythro-
myeloid potential after 8 days of differentiation in WNT3a-containing serum-free 
medium [103].  In agreement with our results, co-culture of hESCs on a Wnt1-producing 
stromal line, which activates canonical Wnt signaling, enhanced differentiation of 
KDR+CD31+CD34+ cells.  This was not observed by activation of the non-canonical 
pathway [104]. 
 The ROCK inhibitor Y-27632 is known to increase viability during hESC 
passaging [105] and has been shown to increase cell survival within the first 24 hours of 
differentiation initiation [93].  Due to the low viability observed during hematopoietic 
differentiation and the heightened concern due to the small culture format, Y-27632 was 
added for initially 48 hours and subsequently 24 hours at day 0 in the stepwise protocol.  
Although Y-27632 has been reported to decrease post-thawing viability and expansion of 
frozen CD34+ cord blood cells [106], we observed no negative effects upon 
hematopoietic differentiation. 
 Previous studies have documented the requirement of VEGF for hematopoietic 
differentiation of ESCs [42, 107, 108], but to our knowledge none had characterized the 
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relationship between concentration and differentiation efficiency.  We directly 
demonstrated that VEGF is required for generating CD34+CD31+ cells and that its 
concentration is proportional to differentiation efficiency.  Furthermore, we showed that 
these cells are also KDR+.  Although we did not characterize the exact identity and 
potential of these cells, it is likely that, prior to emergence of the CD43+ cells, this 
population contains the KDR+ hemangioblast previously described that exhibits 
primitive-erythroid and myeloid potential [19]. 
 CD43 expression marks the commitment of differentiating hESCs to the 
hematopoietic lineage [89].  We first detected CD43+ expression within a population of 
CD43+CD41+CD235+ single cells that emerged between days 7-8 in this system.  We 
found these cells to have primitive-erythroid, megakaryocyte, and myeloid potential.  
Past studies have defined a CD41+CD235+ bipotent primitive erythroid-megakaryocyte 
progenitor (MEP) capable of differentiating towards the primitive erythroid or 
megakaryocyte lineages in both murine embryogenesis [83] and hESC OP9 coculture 
[86].  However, these studies did not assess myeloid potential.  The primitive MEP 
generated by OP9 coculture expressed CD34 shortly after emergence, whereas our 
progenitor did not.  Macrophage potential arises within the murine yolk sac at the same 
time as primitive erythroid potential [80],  indicating that these lines share a common 
progenitor.  Thus, it is difficult to state definitively whether the cell we have generated 
represents an identical or analogous cell type to previous studies.  It is perhaps better 
described as a primitive version the common adult myeloid progenitor [109]. 
 In this study, hematopoietic potential was evaluated based off of entire 
populations of single cells without sorting.  Thus, we can not definitely state which cell 
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possesses common myeloid potential.  Prior studies have demonstrated that unilineage 
CD235+ erythrocytes and CD41+ megakaryocytes arise from CD235+CD41+ bipotential 
progenitors [83], and thus it is reasonable to hypothesize the same here.  We observed 
both CD34+ and CD34- cells within CD41 populations at day 7.  It is not clear if either 
offers more progenitor capabilities.  Zambidis et al. found more colony forming potential 
in CD143+CD34- than in CD143+CD34+ early hematopoietic cells [108].  Chicha et al. 
reported a differentiation system in which CD34+ cells generated myeloid and mature 
erythroid colonies whereas as CD34- cells produced only small immature erythoid 
colonies [90].  The relationship between CD34 expression and progenitor potential is 
clearly not fully understood. 
 IL-3 has been previously shown to enhance primitive erythroid colony formation 
from hESC derived primitive MEPs and has frequently been used in hematopoietic 
differentiation protocols [86, 91].  TPO promotes megakaryopoiesis by binding to its 
receptor c-Mpl [99] and is also commonly utilized in protocols [90, 91, 100, 110].  We 
found that Chir-99021, BMP4, VEGF, and bFGF supplementation were sufficient to 
generate CD43+ committed hematopoietic progenitors and megakaryocytes, but highest 
yields were generated when TPO and IL-3 cytokines were added in combination to the 
differentiation medium.  FLT3L had no apparent effect after 11 days of differentiation.  
In the absence of IL3, IL6 increased hematopoietic yields when used in combination with 
TPO. 
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5. Conclusions, Limitations, and Future Work 
5.1 Conclusions 
 Many clinical therapies could benefit from an in vitro protocol of generating 
hematopoietic cells in a reproducible manner.  Methods to produce both HSCs and 
megakaryocytes, and subsequently platelets, would greatly advance treatment of 
hematopoietic diseases.  Additionally, these protocols could allow further study of 
hematopoiesis during human development.  Many hematopoietic differentiation protocols 
have been published.  However, only a small portion of these are feeder-free and serum-
free, thus allowing clinical translation.  Even fewer allow for target cells to be harvested 
in bulk, and none present an efficient method of producing primitive erythromyeloid 
progenitors and megakaryocytes.  We have created a high throughput assay capable of 
optimizing EB based differentiation of hESCs toward one of the three primary germ 
layers, and applied this assay to create a stepwise serum-free, feeder-free protocol for the 
highly efficient generation of CD41+CD235+ erythromyeloid progenitors and 
CD41+CD42a+ megakaryocytes. 
 We have shown that the 4-color differentiation assay itself can distinguish 
between the three primary germ layers and from undifferentiated pluripotent stem cells 
using the 4 markers as described.  Differentiation toward any lineage could potentially be 
examined by selection of the proper combination of biomarkers.  The use of 4 colors is 
determined by the technical capability of the flow cytometer.  At this point, no 
commercially available instruments exist that allow 96-well plate flow cytometry and are 
capable of more colors.  This is likely to be overcome within several years.  Naturally, 
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more colors would allow for more markers to be assessed, allowing for greater cell 
specification and more elaborate experiments.  At least one 384-well plate flow 
cytometer is available.  However, at this point, in our opinion, EB differentiation within a 
384-well plate would not be possible.  Cell counts would be too low to allow for reliable 
differentiation and accurate analysis. 
 To our knowledge, two other groups have created small-scale differentiation 
optimization assays [23, 26].  Both of these rely upon culturing single EBs within 96-well 
plates.  This allows for precise experiments upon culture conditions and signaling 
pathways to be performed.  Both methods also ensure uniform EB size.  However, hESCs 
undoubtedly release factors into surrounding medium during differentiation.  This cross-
talk between EBs most assuredly would have effects upon differentiation progress, 
course, or efficiency.  Neither method is directly scalable to larger platforms, which 
limits the ability to design a system to supply hematopoietic cells for clinical purposes.  
Our system accomplishes both of these goals.  We have shown scalability to 6-well 
culture for hematopoietic differentiation.  This system also allows highly efficient 
staining and flow cytometry without the need to pool cells. 
 We have defined a primitive hematopoietic EB differentiation protocol using 
stepwise addition of defined differentiation media at specified stages.  By inhibiting 
GSK-3b through the supplementation of Chir-99021, we observed differentiation yields 
of over 80% for Day 3 KDR+ cells, over 70% for day 5 KDR+CD31+ cells, and over 25% 
for day 8 CD43+ CD41+CD235+ primitive progenitors.  We then performed a screen of all 
combinations of four cytokines to enhance day 8 and day 11 CD43+ yields to 
approximately 64% and 104%, respectively.  In summary, we obtained yields of about 
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two CD41+CD235+ primitive hematopoietic progenitors and one CD41+CD42+ 
megakaryocyte for every hESC plated. 
 
5.2 Limitations & pitfalls 
 As with all techniques, this differentiation assay has advantages and 
disadvantages.  It is relevant to highlight the limitations in order to properly interpret 
results and design future experiments accordingly. 
 
5.2.1 Flow cytometry 
 This protocol relies upon a commercially available 96-well flow cytometry unit.  
As previously discussed, only four markers can be assessed simultaneously, limiting the 
conclusions that can be drawn from a single sample.  Furthermore, if markers are only 
expressed transiently, then a given marker combination will only be applicable for a brief 
period of time.  This places limitations on abilities to accurately detect complex 
arrangements of differentiation kinematics.  For ectoderm detection, a NCAM+/SSEA3+ 
identity was utililized.    This is clearly transient as SSEA3 is only expressed within early 
ectoderm.  Thus, if a given condition enhances ectoderm differentiation by quickening its 
pace, the observer may be oblivious due to absence of SSEA3 expression.  If more than 
four colors are desirable, multiple samples must be run and stained separately.  Protocols 
exist for assessing 5 colors simultaneously from a 4 color system, but these were never 
tried. 
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 Generally, it would require 60-90 minutes to read an entire 96-well plate.  
Consequently, some samples would be analyzed 90 minutes apart.  Given the small 
volume, this creates concerns for sample temperature, evaporation, viability, and 
potential differentiation.  Additionally, cells would easily settle during this time, ensuring 
the need for frequent plate agitation.  In order to minimize these confounding variables, 
plates were covered with a lid and kept on ice after staining.  Columns would be 
transferred to a new 96-well round bottom plate one at a time and acquired immediately.  
Round bottom plates were utilized because, according to the manufacturer’s instructions, 
V-bottom plates are not accurate for absolute cell counts.  If only a few columns were 
needed, plate transfer would not be performed, but wells would be agitated by trituration 
with a pipet multichannel just prior to acquisition. 
 
5.2.2 EB dissociation 
 In order to perform accurate flow cytometry, EBs must be dissociated to single 
cells.  In many standard 6-well culture protocols, then entails enzymatic cleavage of 
cellular bonds followed by rigorous trituration with a syringe and needle.  A 96-well plate 
system renders this single sample technique impractical.  Hence, EB dissociation is all 
the more difficult.  For early stage EBs (less than 7-8 days), 0.25% trypsin-EDTA will 
suffice for dissociation.  For larger, later stage EBs, a collagenase incubation period must 
be performed initially, followed by incubation with a harsher agent (such as trypsin).  We 
have observed two caveats that arise from either of these dissociation options. 
 First, some antigens, such as CD41, are especially to trypsin and will be cleaved 
off within several minutes.  This can easily confound results if not expected.  Second, if 
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EBs are not completely dissociated, flow cytometer occlusion will likely occur.  
Additionally, cells within EBs will not be analyzed.  If samples mixed with EBs and 
single cells are dissociated together, this will give a reading that 100% of cells in the 
sample are single cells and artificially inflating differentiation efficiency.  The latter is 
also true if EBs are improperly enzymatically dissociated and too rigoursly mechanically 
separated, resulting in cell death.  Thus, trial experiments should be performed to test 
antigen sensitivity to the applied dissociation agent.  For hematopoietic experiments, we 
found that incubation of cells with Collagenase B for one hour at 37ºC, followed by 5-15 
minutes of accutase incubation at 37ºC with occasional trituration would generally 
suffice.  EBs should be examined with a microscope to ensure disruption. 
 
5.3 Future work 
5.3.1 Hematopoietic differentiation 
 We utilized flow cytometry to characterize cell populations capable of 
multilineage primitive hematopoietic potential.  As a first more thorough assessment of 
the identity of these cells, transcript expression analysis should be performed.  Chir-
99021 supplementation generated quicker differentiation of KDR+ mesoderm cells.  
Brachyury expression should be monitored in the first 3 days to assess the effect of Chir 
upon differentiation to the primitive streak.  Throughout the differentiation process, gene 
expression should be evaluated to verify lineage commitment.  Genes to be evaluated 
include: SCL (hematopoietic commitment), LMO2 (hematopoietic commitment, erythro-
megakaryocytic specification), RUNX1 (hematopoietic commitment, definitive 
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hematopoietic potential), C-MYB (definitive hematopoietic potential, lymphomyeloid 
lineages), GATA2 (hematopoietic commitment), GATA1 (erythro-megakaryocytic 
specification) [89], the megakaryocyte specific genes MPL, FLI1, and the erythrocytic 
specific genes EPOR and KLF1 [86]. 
 In order to further understand the mechanism behind Chir-induced enhancement, 
experiments should be performed to verify that b-catenin phosphorylation is prevented 
and that nuclear translocation occurs.  First, b -catenin phosphorylation could be 
evaluated by staining with a p-b-catenin specific antibody.  Nuclear translocation can be 
verified by immunofluorescence staining of hESCs 24 hours after Chir supplementation.  
B-catenin functionality can be evaluated by evaluating the subsequent activation of 
downstream genes, such as SP5 or AXIN2 [111].  Enhanced proliferation after Chir 
supplementation could be assessed by evaluating BrdU incorporation.  Decreased 
apoptosis could be evaluated by using TUNEL analysis.  Furthermore, colony potential of 
hematopoietic progenitors produced following Chir supplementation should be evaluated. 
 By screening 4 hematopoietic cytokines, we drastically increased the yield of 
progenitors and megakaryocytes.  This yield could likely be increased further by 
screening other commonly utilized cytokines.  A first screen should evaluate EPO and 
SCF.  We observed IL-6 to potentially decrease megakaryocyte specification.  Thus, FP6, 
a soluble form of the IL-6 receptor, could be added to remove any soluble IL-6 [112].  
Additionally, the Notch ligand Delta-like1 (DL-1) has been demonstrated to induce 
megakaryopoiesis from adult HSCs [113].  It would be interesting to conduct a screen 
with recombinant IL-6.  While trends identified by the hematopoietic cytokine screen 
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were consistent and convincing, conclusions drawn from screens should be interpreted 
cautiously.  Future studies will involve follow-up and further validation of these results. 
 Due to the fact that megakaryocytes are difficult to detect in standard 
methycellulose cultures such as that used here, a megakaryocyte-specific culture assay 
(MegaCult, StemCell Technologies) could be utilized.  Additionally, in order to assess 
functionality, fibrin clot assays should be performed upon harvested megakaryocytes 
[86]. 
5.3.2 Differentiation assay 
 By utilization of fluorescent or luminescent reporter genes, this culture system 
could be adapted to endstage readouts other than flow cytometry.  For instance, by using 
Gadue et al.’s Brachyury-driven GFP system, we could perform screens to assess effect 
upon differentiation to the primitive streak [9].  Promoter-specific luciferase cell lines 
would offer the ability to lyse cells and perform efficient viability and luciferase 
measurements by utilization of a plate reader. 
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